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Background: Diet- and physical activity-based interventions in pregnancy have the potential to alter
maternal and child outcomes.
Objectives: To assess whether or not the effects of diet and lifestyle interventions vary in subgroups of
women, based on maternal body mass index (BMI), age, parity, Caucasian ethnicity and underlying
medical condition(s), by undertaking an individual patient data (IPD) meta-analysis. We also evaluated
the association of gestational weight gain (GWG) with adverse pregnancy outcomes and assessed the
cost-effectiveness of the interventions.
Data sources: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Database of Abstracts
of Reviews of Effects and Health Technology Assessment database were searched from October 2013 to
March 2015 (to update a previous search).
Review methods: Researchers from the International Weight Management in Pregnancy Collaborative
Network shared the primary data. For each intervention type and outcome, we performed a two-step IPD
random-effects meta-analysis, for all women (except underweight) combined and for each subgroup of
interest, to obtain summary estimates of effects and 95% confidence intervals (CIs), and synthesised the
differences in effects between subgroups. In the first stage, we fitted a linear regression adjusted for
baseline (for continuous outcomes) or a logistic regression model (for binary outcomes) in each study
separately; estimates were combined across studies using random-effects meta-analysis models. We
quantified the relationship between weight gain and complications, and undertook a decision-analytic
model-based economic evaluation to assess the cost-effectiveness of the interventions.
Results: Diet and lifestyle interventions reduced GWG by an average of 0.70 kg (95% CI –0.92 to –0.48 kg;
33 studies, 9320 women). The effects on composite maternal outcome [summary odds ratio (OR) 0.90,
95% CI 0.79 to 1.03; 24 studies, 8852 women] and composite fetal/neonatal outcome (summary OR 0.94,
95% CI 0.83 to 1.08; 18 studies, 7981 women) were not significant. The effect did not vary with baseline BMI,
age, ethnicity, parity or underlying medical conditions for GWG, and composite maternal and fetal outcomes.
Lifestyle interventions reduce Caesarean sections (OR 0.91, 95% CI 0.83 to 0.99), but not other individual
maternal outcomes such as gestational diabetes mellitus (OR 0.89, 95% CI 0.72 to 1.10), pre-eclampsia or
pregnancy-induced hypertension (OR 0.95, 95% CI 0.78 to 1.16) and preterm birth (OR 0.94, 95% CI 0.78 to
1.13). There was no significant effect on fetal outcomes. The interventions were not cost-effective. GWG,
including adherence to the Institute of Medicine-recommended targets, was not associated with a reduction in
complications. Predictors of GWG were maternal age (summary estimate –0.10 kg, 95% CI –0.14 to –0.06 kg)
and multiparity (summary estimate –0.73 kg, 95% CI –1.24 to –0.23 kg).
Limitations: The findings were limited by the lack of standardisation in the components of intervention,
residual heterogeneity in effects across studies for most analyses and the unavailability of IPD in
some studies.
Conclusion: Diet and lifestyle interventions in pregnancy are clinically effective in reducing GWG
irrespective of risk factors, with no effects on composite maternal and fetal outcomes.
Future work: The differential effects of lifestyle interventions on individual pregnancy outcomes
need evaluation.
Study registration: This study is registered as PROSPERO CRD42013003804.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Maternal obesity and excessive weight gain in pregnancy increase complications in the mother andbaby. These may be reduced by diet and physical activity. It is possible that benefits are restricted to
particular groups of women based on their body mass, age, number of previous children, ethnicity and
underlying medical condition(s). We looked at the effects of diet and physical activity on weight gain in
pregnancy and on the risk of complications in the mother and baby. We obtained anonymised data of
individual participants from multiple studies, and combined them using the technique known as individual
patient data meta-analysis. This was intended to allow us to identify particular groups of women who may
benefit from diet and physical activity.
We established the International Weight Management in Pregnancy Collaborative Network, comprising
anonymised data of 12,343 women from 36 studies. We found that diet, physical activity and mixed
methods, individually and when analysed together, effectively reduced weight gain in pregnancy, possibly
decreased complications in the mother and had no effect on the baby. The effects were similar in all
groups of women.
We did not identify any benefit to mothers or their children when they gained weight within specific
targets that are currently recommended in many countries. A mother’s age and a history of previous births
predicted weight gain in pregnancy.
Diet and physical activity in pregnancy reduced weight gain by 0.7 kg, and had no effect on combined
complications. There were with no differences in these benefits between various groups of women.
The rate of Caesarean section was reduced by the lifestyle intervention compared with usual care.
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Scientific summary
Background
Obesity and excess weight gain in pregnancy are associated with adverse maternal and fetal outcomes.
Maternal age, parity, ethnicity and underlying medical conditions influence the risk of complications.
Diet and physical activities have the potential to reduce weight gain and alter pregnancy outcomes.
Variation in the effect of these interventions across subgroups of women may have implications for clinical
management and provision of care. The association of gestational weight gain (GWG) with complications
in pregnancy needs evaluation using robust data.
Objectives
Primary
1. To assess if the effects of diet- and physical activity-based interventions on (1) GWG, (2) composite
maternal outcomes and (3) composite fetal/neonatal outcomes vary in subgroups of women based on
body mass index (BMI) at booking, age, parity, ethnicity and underlying medical conditions.
Secondary
1. To evaluate the association of GWG and adverse pregnancy outcomes in women and their infants.
2. To assess adherence to the Institute of Medicine (IOM)-recommended weight-gain targets in normal
weight, overweight and obese pregnant women and rates of maternal and fetal complications.
3. To identify the predictors of GWG in pregnancy based on maternal characteristics such as parity,
pre-pregnancy or early pregnancy BMI, ethnicity, smoking, diet, physical activity and socioeconomic
status.
4. To evaluate the cost-effectiveness of interventions.
5. To undertake network meta-analysis to determine the rank order of interventions based on
effectiveness.
Methods
We undertook individual participant data (IPD) meta-analysis by using a prospective protocol in line with
existing recommendations, and complied with the Preferred Reporting Items for Systematic reviews and
Meta-Analysis (PRISMA) guidelines for IPD meta-analysis in reporting our work. We searched MEDLINE,
EMBASE, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects
and Health Technology Assessment database, from October 2013 to March 2015, for relevant studies
(to update a previous search). Randomised trials that assessed the effects of diet, physical activity or
mixed-approach interventions on GWG, composite maternal and fetal/neonatal outcomes were included.
The composite maternal outcome included gestational diabetes mellitus (GDM), pre-eclampsia (PE) or
pregnancy-induced hypertension (PIH), preterm delivery and Caesarean section. The composite fetal
outcomes included intrauterine death, small for gestational age, large for gestational age and admission to
the neonatal intensive care unit (NICU). Researchers from the International Weight Management in
Pregnancy Collaborative Network shared the primary data.
We obtained summary estimates of effects and 95% confidence intervals (CIs) for each intervention type
and outcome, with a two-step IPD random-effects meta-analysis, for all women combined and for each
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subgroup of interest. We synthesised the differences in effects between subgroups in a two-step IPD
random-effects meta-analysis. In the first stage, we either fitted a linear regression adjusted for baseline
(for continuous outcomes) or a logistic regression model (for binary outcomes) in each study separately; in
the second stage, the pertinent effect estimates were then combined across studies using a random-effects
meta-analysis model estimating via restricted maximum likelihood. We quantified the relationship between
weight gain and pregnancy complications. A model-based economic evaluation was undertaken to assess
the cost-effectiveness of the interventions.
Results
Of the 74 eligible studies (17,727 women), 36 (12,434 women) contributed data to the IPD meta-analysis:
33 (9320 women) evaluated GWG, 24 (8852 women) reported all four components of the composite
maternal outcomes and 18 (7981 women) assessed all four components of the fetal/neonatal
composite outcomes.
Effect of diet- and physical activity-based interventions on maternal and
fetal outcomes
Diet- and physical activity-based interventions reduced GWG by an average of –0.70 kg [95% CI –0.92 to
–0.48 kg, 95% prediction interval (PI) –1.24 to –0.16 kg; 33 studies, 9320 women] compared with the
control group in the IPD meta-analysis. The odds of composite adverse maternal outcome were not
significantly reduced by the interventions [summary odds ratio (OR) 0.90, 95% CI 0.79 to 1.03, 95% PI
0.68 to 1.20]. The interventions had no effect on fetal/neonatal outcomes (summary OR 0.94, 95% CI
0.83 to 1.08, 95% PI 0.74 to 1.21).
The IPD meta-analysis showed a significant reduction in rates of Caesarean section (OR 0.91, 95% CI 0.83
to 0.99; 32 studies contributing data, 11,410 women). The decreases in rates of other individual maternal
outcomes [such as GDM (OR 0.89, 95% CI 0.72 to 1.10; 27 studies contributing data, 9427 women), PE
or PIH (OR 0.95, 95% CI 0.78 to 1.16; 22 studies, 9618 women) and preterm birth (OR 0.94, 95% CI 0.78
to 1.13; 32 studies contributing data, 116,876 women)] were not significant.
Sensitivity analysis showed that the beneficial effect on weight gain persisted after adding non-IPD data
(summary mean difference –1.13 kg, 95% CI –1.58 to –0.68 kg; 60 studies, 12,895 women). Meta-analysis
of published aggregate data showed a significant reduction only in GDM (OR 0.78, 95% CI 0.64 to 0.95;
29 studies, 11,118 women) and Caesarean section (OR 0.90, 95% CI 0.82 to 0.99; 37 studies, 11,340
women) compared with the control group. There were no significant reductions in preterm birth (OR 0.80,
95% CI 0.63 to 1.01; 23 studies, 7480 women) and PE or PIH (OR 0.89, 95% CI 0.75 to 1.05; 20 studies,
9198 women). Both aggregate and IPD meta-analyses did not have an effect on fetal/neonatal outcomes.
Differential effect of interventions on gestational weight gain and
pregnancy outcomes
The effect of interventions on GWG did not significantly vary with maternal BMI (–0.02 kg change in
intervention effect per 1 kg/m2 increase in BMI, 95% CI –0.08 to 0.04 kg), age (–0.03 kg change in intervention
effect per 1-year increase in age, 95% CI –0.08 to 0.02 kg), parity (0.10 kg change in intervention effect for
multiparity vs. nulliparity, 95% CI –0.39 to 0.60 kg), ethnicity (0.05 kg change in intervention effect for
non-Caucasian vs. Caucasian, 95% CI –1.27 to 1.37 kg) or underlying medical conditions (1.51 kg change in
intervention effect for women with at least one condition vs. none, 95% CI –2.01 to 5.02 kg).
We did not identify any significant change in treatment effect for composite maternal outcomes in
subgroups based on maternal BMI (no change in effect for every 1 kg/m2 increase in BMI, OR 1.00, 95% CI
0.98 to 1.02), age (1% increase in effect for every 1-year increase in age, OR 1.01, 95% CI 0.99 to 1.03),
parity (3% increase in effect for multiparity vs. nulliparity, OR 1.03, 95% CI 0.75 to 1.39), ethnicity
(7% decrease in effect for non-Caucasian vs. Caucasian, OR 0.93, 95% CI 0.63 to 1.37) or underlying
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medical conditions (44% increase in effect for women with at least one condition vs. none, OR 1.44, 95% CI
0.15 to 13.74). For composite fetal/neonatal outcome we observed a 2% lowered effect (OR 0.98, 95% CI
0.95 to 1.00) for every 1 kg/m2 increase in booking BMI, which was of borderline significance. There was no
significant treatment–covariate interaction for other factors and composite fetal/neonatal outcome. There
was significant evidence of small-study effects for GWG (Egger’s test, p = 0.038) and the composite
maternal outcome (Peter’s test, p = 0.036), but not for fetal/neonatal composite outcome (p = 0.398).
Gestational weight gain and pregnancy outcomes
We did not identify an association between GWG, booking BMI and risk of maternal (summary OR 1.03,
95% CI 0.93 to 1.15) or fetal/neonatal complications (summary OR 1.02, 95% CI 0.91 to 1.15).
Adherence to IOM criteria for GWG did not significantly reduce GWG. Increase in maternal age (–0.1 kg,
95% CI –0.14 to –0.06 kg) and multiparity (–0.73 kg, 95% CI –1.24 to –0.23 kg) were significantly
associated with GWG.
We refrained from undertaking network meta-analysis, as there were no differences in estimates of effect
for GWG between diet-based, physical activity-based and mixed-approach interventions.
Cost-effectiveness of the intervention
Diet- and physical activity-based interventions in pregnancy are not cost-effective compared with
usual care. Although the primary base-case analysis indicated a small reduction in pregnancy-related
complications, the probabilistic sensitivity analysis showed no evidence of significant difference between
the intervention and the control arms for either cost or clinical effectiveness. Similarly, the results of the
secondary analysis for obese, overweight and normal weight women found no evidence that diet- and
physical activity-based interventions are more cost-effective than usual care for any of the subgroups.
Conclusions
Interventions based on diet and physical activity in pregnancy reduce GWG, and the effect does not vary
by maternal BMI, age, parity, ethnicity or underlying medical conditions. The interventions do not confer
any additional benefit for composite maternal and fetal outcomes and are not cost-effective. There is no
evidence to support routine use of IOM targets for GWG.
Recommendations for further research
The impact of lifestyle interventions in pregnancy on long-term outcomes (such as postpartum weight
retention, future risk of diabetes and hypertension, subsequent pregnancy outcomes and childhood
obesity) needs evaluation. Randomised trials are required to evaluate the effect of interventions to optimise
the pre-pregnancy health of the mother.
Study registration
This study is registered as PROSPERO CRD42013003804.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Updated data can be found in the meta-analysis by the International Weight Management in Pregnancy(i-WIP) Collaborative Group.1
Obesity is an epidemic. In the UK, every other woman of childbearing age is either overweight [body mass
index (BMI) of 24.9–29.9 kg/m2] or obese (BMI of 30 kg/m2 or more), and one-fifth start pregnancy as
obese.2 The confidential enquiry into maternal and child health identified maternal obesity as a threat to
the childbearing population in the UK.3 The risks for the infant include stillbirth and neonatal death,
macrosomia, neonatal unit admission, preterm birth and congenital abnormalities. In the longer term,
maternal obesity is associated with an increased risk of childhood obesity and associated complications.4
A significant proportion of women gain more than the recommended weight during pregnancy,5 with
increased risk of maternal and fetal/neonatal complications.6 Women who gain excess weight in pregnancy
are at increased risk of postpartum weight retention. This predisposes normal weight and overweight
women in index pregnancy into entering subsequent pregnancies as overweight or obese. Effective
interventions that reduce maternal obesity and excess weight gain in pregnancy could derive significant
advantages for the NHS and society.
Clearly defined, effective interventions that target those women at the highest risk in pregnancy are
needed. Diet- and physical activity-based interventions have been widely evaluated for their effect on
gestational weight gain (GWG) and clinical outcomes. There is limited information on their effects
on specific groups of pregnant women known to be at increased risk of complications.
Aggregate meta-analysis of randomised trials on diet- and physical activity-based interventions [Health
Technology Assessment (HTA) programme reference number 09/27/06] showed a significant reduction in
GWG, with benefit for some clinical outcomes.7 However, aggregate data meta-analysis was limited
because of the inability to explain heterogeneity of effects for important maternal and fetal/neonatal
outcomes. This heterogeneity might be a result of variation in maternal characteristics, such as BMI, age,
ethnicity and parity with varied weight gain.
Pregnancy during adolescence alters normal growth processes and increases the risk of becoming
overweight or obese.8 Adolescent mothers retain more weight post partum than mature control subjects.8
Inclusion of a large number of pregnant adolescents may overestimate postpartum weight changes or the
risk of becoming overweight, and thus bias estimates for adult women. Migrant groups exhibit less GWG
than the local population but similar rates of complications.9 These aspects need investigation.
The National Institute for Health and Care Excellence (NICE) public health guidance Weight Management
Before, During and After Pregnancy10 has prioritised the following areas for research: the clinical
effectiveness and cost-effectiveness of weight management interventions in pregnancy for specific groups,
such as teenagers, with differing needs and social circumstances; ethnic minorities, such as Asians, in
whom comorbidity risk at any particular BMI value is relatively higher than in other ethnic groups; women
who enter pregnancy obese; and the effect of adherence to the Institute of Medicine (IOM)’s weight-gain
recommendations on pregnancy outcomes.
The paucity of published detail in research on the effects of interventions in particular subgroups of
women based on BMI, ethnicity and other relevant factors restricts aggregate data meta-analyses.11,12
Subgroup effects are rarely reported in sufficient detail, especially to derive differences in intervention
effect between subgroups (‘treatment–covariate interactions’). Meta-regression examining the across-trial
association between overall treatment effect and average patient characteristics (e.g. mean age) has low
power to detect genuine subgroup effects and is also prone to study-level confounding.13,14 Furthermore,
the available data could not assess the impact of baseline prognostic factors on the effectiveness of the
interventions. Meta-analysis of individual participant data (IPD),15 in which the raw patient-level data are
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1
obtained and synthesised across trials, overcomes the above limitations. Availability of the raw data
substantially increases the power to detect baseline factors that truly modify intervention effect13 and
enables intervention effects to be quantified for clinically relevant groups.16 It will also allow the magnitude
of benefit, due to weight change in pregnancy, to be quantified for both the women and their infants.
We undertook an IPD meta-analysis of randomised trials on diet- and physical activity-based interventions
to assess differential effects of interventions in various subgroups of pregnant women.
BACKGROUND
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Chapter 2 Objectives
Primary
1. To assess if the effects of diet- and physical activity-based interventions on (1) GWG, (2) composite
maternal and (3) composite fetal/neonatal outcomes vary in subgroups of women based on BMI at
booking, age, parity, ethnicity and underlying medical conditions.
Secondary
1. To quantify the relationship between the amount of weight gained in pregnancy and the risk of adverse
maternal and fetal/neonatal outcomes for (1) women of normal weight, (2) overweight women and
(3) obese women.
2. To assess the relationship between adherence to IOM’s guidelines and maternal and fetal complications
in normal weight, overweight and obese pregnant women.
3. To identify the predictors of GWG in pregnancy based on patient characteristics such as parity,
pre-pregnancy BMI, ethnicity, smoking, diet and lifestyle, and socioeconomic status.
4. To assess the cost-effectiveness of the interventions in pregnancy using model-based full economic
evaluation with value of information analysis.
5. To undertake network meta-analysis to determine the rank order of interventions for clinical effectiveness,
if appropriate.
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Chapter 3 Methods
Our IPD meta-analysis followed existing guidelines and used a prospective protocol registered withPROSPERO (CRD42013003804).17 Our output complied with the Preferred Reporting Items for
Systematic reviews and Meta-Analysis (PRISMA) reporting guidelines for IPD meta-analysis.18
Eligibility criteria
Criteria for including studies in individual participant data
We included studies that addressed the components of the structured question presented in Table 1.
Randomised trials, with or without clustering, that evaluated the effects of diet- and physical activity-based
interventions in pregnancy on maternal, fetal and neonatal outcomes were eligible for inclusion. We
included studies on normal, overweight and obese pregnant women. Interventions that addressed mainly
diet or mainly physical activity and interventions adopting a mixed approach that combined the two, with
or without behavioural modification techniques, were eligible. The control arms included women without
any intervention or with routine antenatal care, as defined by local health-care practices. The primary
outcomes were maternal weight gain in pregnancy, and composite maternal and composite fetal/neonatal
events complications. Studies should have assessed both maternal weight gain and clinical outcomes.
Maternal weight gain was defined as the difference between the weights recorded (kg or lb) at first
clinic visit and last weight measured before birth. If weight at first clinic visit was not available, we used
pre-pregnancy weight.
The maternal composite outcome included gestational diabetes mellitus (GDM), pre-eclampsia (PE) or
pregnancy-induced hypertension (PIH), preterm delivery and Caesarean section. The fetal and neonatal
composite outcome comprised intrauterine death (IUD), small for gestational age (SGA), large for gestational
age (LGA) and admission to the neonatal intensive care unit (NICU). The components of the composite
outcome were identified by a two-round Delphi survey. The final scores of the components are provided in
Appendix 1. The details of the development of the composite outcomes are published elsewhere.19
We excluded studies published before 1990, animal studies and those that evaluated the effects of
intervention only on non-clinical outcomes (behaviour change and consumption of particular food groups)
or aimed to increase weight gain in pregnancy.
TABLE 1 Structured question for IPD meta-analysis of diet- and physical activity-based interventions on maternal
and fetal/neonatal outcomes
Component Description
Population Pregnant women with a BMI of ≥ 18.5 kg/m2
Interventions Diet-based, physical activity-based and mixed-approach intervention
Comparison No intervention or routine antenatal care
Main outcomes GWG, maternal composite outcome, fetal and neonatal composite outcome
Other outcomes Maternal: gestational diabetes mellitus, pre-eclampsia or pregnancy-induced hypertension,
preterm delivery (< 37 weeks), Caesarean section
Fetal/neonatal: intrauterine death, small for gestational age fetus, large for gestational age fetus,
admission to the NICU
Study design Randomised controlled trial
NICU, neonatal intensive care unit.
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Criteria for including participants in individual participant data
We excluded underweight women (BMI of < 18.5 kg/m2) and women with multiple pregnancies.
Literature search and study identification
We updated our previous literature search (October 2013 to March 2015) to identify new trials published
since the completion of our systematic review (HTA number 09/27/067) on effects of diet- and physical
activity-based interventions in pregnancy. The following databases were searched from October 2013 to
March 2015 to update the search: MEDLINE, EMBASE, Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects and HTA
database without any language restrictions. We used additional sources, such as the internet [general
search engines such as Google (Google Inc., Mountain View, CA, USA)], and directly contacted researchers
to identify relevant trials. We did not contact authors of trials that were published or identified too close
to the analysis stage because of lack of sufficient time to clean and format the data before analysis.
The details of the search strategy are provided in Appendix 2.
We established the International Weight Management in Pregnancy (i-WIP) IPD Collaborative Network by
contacting researchers who had published trials on diet and lifestyle interventions in pregnancy.20 The
network is a global effort in bringing together researchers, clinicians and epidemiologists involved, supported
by the World Health Organization, from 16 countries (https://kamolo.org.ar/iwipipd, accessed 1 March 2016).
Study and participant selection
Study selection
We undertook a two-stage study selection process. In the first stage, the abstracts of all citations were
evaluated for their eligibility. In the second stage, we studied the identified studies in detail before their
inclusion. Two independent reviewers (ER and EM) evaluated all papers. In case of disagreement, an opinion
of the third reviewer (ST) was sought. We applied the eligibility criteria provided above for inclusion of studies.
Data collection and storage
We set up a bespoke database and requested authors of the i-WIP Collaborative Network to supply data in
any format [Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA), IBM SPSS Statistics versions 22
and 23 (IBM Corporation, Armonk, NY, USA), Stata (StataCorp LP, College Station, TX, USA) and SAS
(SAS Institute Inc., Cary, NC, USA)] convenient to them. We sent, on average, three reminders when there
was no response. For studies that refused to provide IPD, and for those with which contact could not be
established, we extracted the published aggregate data.
We obtained and uploaded the original anonymised data sets using the secure web-based server at Centro
Rosarino de Estudios Perinatales, Rosario, Argentina, a World Health Organization Collaborative Centre in
Child and Maternal Health. Data manipulations were performed and documented within this environment.
The final meta-data set was securely transferred to the Pragmatic Clinical Trials Unit at Queen Mary
University of London for final data checks and analysis. An independent data access committee and data
access process were established for use of the data in future research.
Data items
We considered all recorded variables for inclusion when appropriate, including those not reported in the
published studies. Data were extracted on the study and data set levels. At the study level, we collected
information regarding study settings, intervention type, components, format and provider. At the
participant level we requested information on individual characteristics including BMI, age, parity, ethnicity,
socioeconomic status, pre-existing medical conditions, adherence to intervention and outcome data. The
list of final variables collected during the project is available in Appendix 3.
METHODS
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Definition and standardisation of variables
Participant characteristics and other measurements were recorded in various different formats within the
individual data sets. We chose the meta-data set format by including the variables that were most
commonly reported. The standardisation process followed a predefined procedure (Figure 1).
Standardisation of baseline variables
Maternal age (years) at baseline was recorded as a continuous variable in most studies except one,
in which age at baseline was calculated from the date of first visit and the date of birth. In addition to
continuous data, we used the cut-off point of 20 years for age, to dichotomise participants into teenagers
and those over 19 years. Race/ethnicity was recorded in a variety of ways and standardisation required a
larger number of assumptions to be made. The details of ethnicity coding are available in Appendix 4. BMI
was recorded both as a continuous measure and categorised into clinically relevant categories as normal
weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2) and obese (≥ 30 kg/m2).
We used the woman’s educational status to represent the socioeconomic status by using local standards.
After feedback from the study team we defined educational status as ‘low’ (secondary education completed
before A-levels), ‘medium’ (secondary education to A-level equivalent) or ‘high’ (any further/higher
education) (see Appendix 4). Smoking was generally recorded as yes/no, with some studies recording
previous habits. If the woman had stopped smoking because of pregnancy or for other reasons at any time
point, this was combined into the variable for ‘ex-smoker (yes/no)’.
We defined participants as adherent if they completed around 70–80% of the intervention protocol, if the
data set provided adherence information in a yes/no format or if non-adherent women were excluded as
per study protocol. Parity was defined as the number of times participants had given birth before the index
pregnancy and was recorded consistently across the data set. We combined information from physical
activity questionnaires, gym attendance, type of work and accelerometer data to standardise the approach
A. First quality 
    check
B. Upload onto 
    the database
C. Conversion to
    SAS format
DS in SAS format 
where the names of 
the variables are as in 
the original data set
Visualisation of the
variables lists with
their names and labels
DS with selected 
variables with the 
variables’ names 
harmonised where
possible
Individual DS ready
for merging
Visualisation of 
variables summary
on the web
DS stored in the
repository
Interim DS
DS stored in the 
repository
D. Selection of the 
    essential variables
E. First harmonisation
    of the variables’
    names
Original DSStage
Output
Action
SAS DS Essential DS Core DS Meta DS
Final DS
F. Transformation 
    and second 
    harmonisation of 
    the variables’ names
G. Second quality 
    check H. Merging
FIGURE 1 Flow diagram of standardisation of variables within the IPD sets. Interim DS refers to a temporary
work-in-progress data set that will not be stored onto the database. DS, data set.
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for baseline physical activity (for details see Appendix 4). Previous macrosomia and GDM were defined as
per individual study authors and were recorded in all data sets as ‘yes/no’.
Standardisation of outcome variables
Weight was standardised to kilograms and height to centimetres. BMI was defined as weight/height
squared (kg/m2) and was consistently reported across all data sets. Baseline obesity was defined as a
BMI of ≥ 30 kg/m2. Adherence to the IOM recommendations for GWG was as follows: 11–16 kg for
normal weight women, 7–11 kg for overweight women and 5–9 kg for obese women.9 We classified
women as not reaching the recommendation (i.e. GWG less than the lower limit), adherent (i.e. GWG
within limits) or exceeding the recommendation (i.e. GWG more than the upper limit).
Gestational diabetes mellitus, diabetes mellitus (DM), PIH, PE, chronic hypertension and Caesarean section
were defined and reported in the data sets in accordance with local standards. IUD and admission to the
NICU were analysed as defined in the data set. Outcomes SGA (< 10th centile) and LGA (≥ 90th centile)
were generated for all data sets using a bulk birthweight centile calculator [Gestation Related Optimal
Weight (GROW) customised centiles (CC) software, version 6.7; Gestation Network, Birmingham, UK,
2013] incorporating data on women’s height and baseline weight, parity, gestational age at birth and
fetal birthweight.
Data quality (individual participant data integrity)
Data sets included in the i-WIP analysis were expected to be clean on receipt from the original trial team.
We performed range checks on the variables used during the analysis and produced summary tables.
We focused on checking the randomisation ratio, baseline characteristics and the method of analysis in the
IPD data set with the published information. Any major discrepancies were discussed with the trial team.
Risk-of-bias assessment in individual studies
We evaluated the risk of bias in individual studies by considering six items used in the Cochrane risk-of-bias
tool: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome
reporting and other potential sources of bias.21 When required, we obtained the full trial protocol and
directly contacted the primary investigators to obtain relevant details to assess the study quality. A study
was classified as having a high risk of bias if it was assessed as high risk in at least one of the following
domains: randomisation, allocation concealment, blinding of outcome assessment, incomplete outcome
data and when no single item was assessed as being at low risk of bias.
Handling of trials without individual participant data availability
We explored the potential for publication bias, and the possible impact of unavailable non-IPD data, in
accordance with recent guidelines.22 For each analysis containing 10 or more studies, the potential for
publication bias was investigated through contour-enhanced funnel plots, and appropriate statistical tests for
‘small-study effects’ (i.e. the tendency for small studies to provide more positive findings than large ones).
For all studies in which IPD were not available, we extracted suitable aggregate data from the study
publications. When possible, we then incorporated these aggregate data into the second stage of the
two-step meta-analysis framework, to combine the IPD trials with the aggregate data from other trials
for the outcome of GWG. This allowed us to examine whether or not conclusions (on summary results and
potential publication bias) were changed by the inclusion of additional non-IPD trials.14,23 If the inclusion of
studies that did not provide IPD seemed to have an important statistical or clinical impact, we compared
the characteristics of the studies with IPD with those without to see if there were any key differences (such
as in their quality, follow-up length and statistical methods). This was achievable only when examining the
overall treatment effect, as aggregate data for subgroup effects were rarely provided by the non-IPD
studies. For individual maternal and fetal/neonatal complications, we compared meta-analyses findings of
only aggregate published data with IPD.
METHODS
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Sample size considerations
Although no formal sample size requirements are necessary for the meta-analysis, we have considered the
potential power of our IPD meta-analysis in comparison with single trials in this field to detect clinically
important effects in each subgroup separately. All calculations relate to a type I error of 5%, a power of
80% and a loss to follow-up of 5%. We chose a reduction of 2.5 kg in GWG as the minimally important
difference. We expected the available sample size to be > 9000 women. For maternal weight gain, the
sample size required for all subgroups is ≤ 300. For the composite outcome of adverse maternal and
fetal/neonatal outcomes, we calculated the sample size needed to detect an intervention effect of a 30%
reduction in adverse pregnancy outcomes. Our estimates of the standard deviation (SD) of the control
group and the risk of composite pregnancy outcome were obtained from the data of primary studies
included in our systematic review.24
Given the large sample size available, it is highly likely that the study was powered to detect important
differences between subgroups (i.e. to identify genuine factors that modify treatment effect). This allowed
us to detect interaction terms as small as about 30% of the size of the overall treatment effect. If the
overall intervention effect is a reduction in weight gain of approximately 2.5 kg, then our IPD meta-analysis
would have 80% power to detect an interaction term of about 2.5 × 0.3 = 0.75 or above (e.g. a difference
in intervention effect of 0.75 kg between obese and normal weight women) (Table 2).
Data analysis
All analyses were carried out using Stata, version 12.1. Aggregate meta-analyses for components of
maternal and fetal/neonatal composites were done using Review Manager, version 5.3 (The Nordic
Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark).
TABLE 2 Sample size estimations for various subgroups to evaluate the effect of interventions on weight gain and
pregnancy outcomes in a single trial
Subgroups
Control
group SD
Sample size required
to detect a 2.5-kg
reduction in GWG
Control group
probability of adverse
pregnancy outcome
Sample size required to
detect a 30% reduction in
adverse pregnancy outcome
BMI category
Obese 7.5 300 0.30 770
Overweight 7.5 300 0.20 1290
Normal weight 5.1 140 0.12 2330
Age (years)
< 20 7.12 270
≥ 20 5.87 184
Ethnicity
Caucasian 3.4 64
Asian 3.8 78
African 5.1 140
Parity
< 1 6.28 212
≥ 1 6.68 238
Risk factors such as diabetes
High risk 6.81 248
Low risk 6.67 236
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Primary analyses of studies providing individual participant data
For each outcome (i.e. GWG, composite maternal, composite fetal/neonatal) separately, we performed a
two-stage IPD meta-analysis to obtain summary estimates and 95% confidence intervals (CIs) for the
intervention effects [mean difference (MD) or odds ratios (ORs)] and the interactions (subgroup effects)
of interest. All participants were analysed according to the group they were randomised to. We used a
two-stage random-effects meta-analysis approach, which allows for between-study heterogeneity in
intervention effect (and interaction effect). In any two-stage meta-analysis, the clustering of participants
within trials is accounted for by analysing each trial separately in the first stage. Women with confirmed
glucose intolerance or hypertensive disorder at baseline, as defined by the primary authors, were excluded
in the analysis of composite adverse pregnancy outcomes.
First stage of individual participant data meta-analysis
Continuous outcome measures were checked for normality and log transformed if applicable. Variables
(covariates) were kept as continuous as well as defining subgroups for BMI and maternal age. All analyses
were performed on complete cases, that is individuals who provided the outcome and (if relevant for the
analysis) baseline adjustment factors. When analysing cluster randomised trials, we included a random
intercept for the unit of randomisation to account for clustering. For the continuous outcome of weight
gain, we used analysis of covariance in each trial to regress the final weight value against the intervention,
while adjusting for baseline weight. For the binary outcome of adverse fetal/neonatal or maternal
outcome, the binomial nature was modelled using a logistic regression in each trial separately, with
intervention as a covariate. Stratification or minimisation factors used in the randomisation of each study
were not adjusted for in any analyses. The Sweeting et al.25 approach was applied to include studies into
the analysis of composite outcomes that had no information on outcome for one treatment group.
This was only done for the primary analysis without interaction terms.
When examining intervention effect modifiers, we extended the models to include interaction terms
between participant-level covariates and the intervention. For the interactions, continuous covariates
(BMI and age) were analysed on continuous scales and as clinically defined categorical values. In addition,
effects were presented within the subgroups defined by the interactions.
All primary analyses were performed on the combined intervention and any multiple treatment arms were
combined into one intervention arm. For the secondary analysis of individual intervention types, multiple
treatment arms were combined if they belonged to the same type, for example brochure arm and active
counselling were grouped as mixed-approach intervention) or analysed separately if the treatment arms
were categorised as different types (e.g. exercise and exercise plus dietary counselling).
Second stage of individual participant data meta-analysis
We pooled effect estimates (e.g. relating to treatment effects or treatment–covariate interactions) using a
random-effects model using restricted maximum likelihood (REML) to produce a summary effect estimate
for the mean (or average) effect across studies. The Knapp–Hartung correction was applied when deriving
95% CIs for each summary effect, to account for the uncertainty of the estimate of between-study
heterogeneity (τ2). Forest plots were generated to display the study-specific and pooled results.
Heterogeneity was summarised using the I2 statistic and the estimated between-study variance (τ2) was
obtained using REML. To reveal the impact of heterogeneity more clearly, we also calculated approximate
95% prediction intervals (PIs) for the intervention (or interaction) effect in a new study using the formula
suggested by Higgins et al.26
Sensitivity analyses
Small-study effects (and the potential for publication bias) were investigated by using contour-enhanced
funnel plots and tests for asymmetry (using either the Egger’s test for continuous outcomes or Peter’s test
for binary outcomes). In order to examine whether or not there may be availability bias in the obtained
IPD, we compared summary results when including non-IPD studies with those in our IPD studies.
METHODS
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When possible, we then incorporated this aggregate data into the second stage of the two-step meta-
analysis framework (see below), to combine the IPD trials with the aggregate data from other trials, to
ascertain if conclusions were robust.
We investigated the following sources of bias for all or a subset of the primary outcomes by performing
the following sensitivity analyses.
Study quality
We excluded studies at high risk of bias in at least one of the following domains: randomisation, allocation
concealment, blinding for outcomes assessment or completeness of outcome data, and not a single item
of low risk.
Intervention
We analysed the primary outcomes separately for each intervention type (diet, physical activity and mixed)
to ensure that the analysis of the combined intervention was valid.
Adherence
We excluded any participants not adherent to their intervention.
Outcome measurement
We analysed BMI change instead of weight change to assess the impact of those studies that reported
only on BMI and not weight. The effect of timing of gestational weight measurement on the effects was
addressed by excluding weights measured before 37 completed weeks of gestation to exclude systematic
differences. We analysed each component separately to ensure validity of the composite outcome.
Secondary analyses
All secondary analyses were performed only on participants in control arms to exclude the effect of
treatment.
Quantification of the relationship between gestational weight gain and risk
of outcome
For each composite outcome separately, we fitted two-stage meta-analysis models (logistic regression in
stage 1, followed by a random-effects meta-analysis in stage 2) to obtain a pooled estimate of how each
1-unit increase in weight gain changed the risk of a poor outcome depending on baseline BMI. Baseline
BMI remained a continuous variable.
We assessed if adherence in pregnancy to IOM weight-gain recommendations was associated with a
reduced risk of adverse pregnancy outcomes in normal weight, overweight and obese women. We used
the two-stage logistic framework as described above, with a covariate for adherence to IOM. Baseline BMI
was included as categorical (normal weight/overweight/obese) using the same cut-off points as the
definition for IOM adherence. Adherence was defined in three categories as below IOM, adherent to IOM
and exceeding IOM recommendations for weight gain.
Evaluation of factors associated with weight change in pregnancy
We evaluated those variables that may be associated with GWG including age, ethnicity, underlying
medical conditions like DM, parity and socioeconomic status. To obtain adjusted factor results, a
multivariable model was fitted including all variables reported in at least 10 studies to identify those that
were independently associated.
Network meta-analysis
We refrained from undertaking network meta-analysis, as there were no differences in estimates of effect
for GWG between diet, physical activity and mixed-approach interventions.
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Chapter 4 Characteristics and quality of studies
included in the individual participant data
meta-analysis
Study selection and individual participant data acquisition
Our previous search (until 2013) had identified 44 randomised trials.7 We identified 3551 potentially
relevant citations (Figure 2). We also identified 57 potential papers from references of included studies and
four from oral communications. Detailed evaluation of the 167 articles led to the final identification of
74 trials (n = 17,623) on diet- and physical activity-based interventions in pregnancy (see Figure 2).
We invited the authors of 58 trials to join the project and share the IPD. Forty-one researchers from
29 teams, in 16 countries, joined the i-WIP Collaborative Network (until October 2015) and provided access to
anonymised individual data on 12,343 women. The collaborators included obstetricians, academics, dietitians,
nutritionists, physiotherapists, exercise physiologists, psychologists and clinical epidemiologists.
The most common combined reason for not being able to obtain IPD was difficulty in contacting the
authors and contact loss (11/58).28–38 Reasons for refusal to provide IPD included lack of time,39,40 problems
with data sharing41 and conflicts of interest.42,43 Data were lost in two trials.44,45 Sixteen randomised
controlled trials (RCTs) (including 2265 women) were identified too late in the project to be analysed, and
thus we refrained from approaching the authors.46–61 Most of these studies evaluated physical activity-based
interventions (10 trials) and/or were conducted in developed countries (10 trials). Details of all 16 studies are
provided in Appendix 5.
Characteristics of the studies included in the individual participant
data analysis
Thirty-six RCTs contributed IPD to this project. Thirty-four trials were randomised trials with individual
participant allocation and two were cluster RCTs.62,63 Twenty-two trials were conducted in Europe, four in
each of North America (three in the USA and one in Canada), Australia and South America (Brazil) and
one each in Egypt and Iran. The size of the studies ranged from 12 to 2212 women. Eight studies included
only obese women,64–71 three included obese and overweight women,72–74 one included overweight
women75 and 24 included women of any BMI. Four trials assessed diet-based interventions,71,76–78
16 evaluated physical activity,27,42,67,75,79–89 and 15 trials adopted a mixed approach (diet, physical activity,
behaviour-modifying techniques, etc.).62–66,68,70,72–74,90–94 Four trials had a three-arm design (two interventions
and routine care arm).27,64,66,69 Of these, in three, interventions belonged to the same type (different type of
counselling or different exercise routine).27,64,66 In one trial, one arm of the intervention comprised exercise
only and the other a combination of exercise and diet (mixed approach).69 GWG was reported as an
outcome in 57 studies; 33 provided IPD and in 27 studies only aggregate data were available. The
numbers of studies reporting rates of individual maternal and fetal/neonatal outcomes are given in Table 3.
Overall, 38 eligible studies (38/74, 51.4%) comprising 5280 women did not contribute IPD. Table 3
compares the characteristics of studies that did and did not share IPD for the meta-analysis. The detailed
descriptions of all trials are provided in Appendix 6.
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FIGURE 2 Flow diagram of studies in the IPD systematic review, showing the studies included in the review
and meta-analysis.27
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Characteristics of the individual participants in the individual
participant data meta-analysis
The average age of participants was 30 years in both arms of the trials. More than 80% of participants
were of Caucasian ethnicity. About half of the participants had obtained a higher degree, were nulliparous
and were not physically active. Table 4 shows a detailed comparison of baseline characteristics in both
arms of the studies that contributed to the IPD.
The most common outcomes available in studies that contributed IPD were preterm delivery (11,731 women,
34 studies), Caesarean section (11,585 women, 34 studies) and SGA (11,682 women, 34 studies) and LGA
(12,078 women, 36 studies) fetuses. This was followed by GWG (9320 women, 33 studies), PE (8350 women,
20 studies), PIH (9065 women, 25 studies) and GDM (9882 women, 30 studies). We were able to obtain
maternal and fetal/neonatal outcome based on available individual data of 8852 (24 studies) and 8239
(19 studies) participants, respectively (Table 5).
TABLE 3 Brief characteristics of trials available and unavailable for the i-WIP IPD meta-analysis
Characteristics
Availability of IPD (number of studies)
Available (n= 36 studies,
n= 12,526 women)
Unavailable (n= 38 studies,
n= 5280 womena)
Population
Any BMI category 24 27b
Obese or overweight 12 11
Intervention type
Diet based 4 9
Exercise based 16 19
Mixed approach 16c 10
Outcomesa
GWG 31 27
GDM 20 11
PE or PIH 15 6
Preterm delivery 16 8
Caesarean section 22 16
IUD 4 0
SGA 6 4
LGA 11 4
Admission to the NICU 4 2
Country of conduct
Developed 30 26
Developing 6 12
a Based on the numbers given in the published trials reports.
b Li et al.55 recruited women with BMI within normal range.
c Renault et al.69 was classified as a mixed-approach study.
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TABLE 4 Baseline characteristics of patients in studies that contributed to the IPD
Baseline characteristics
Number of
studies
Number of
women
Study arm, mean (SD) or n (%)a
Control Intervention
Age (years) 35 12,006 30.1 (5.2) 30.0 (5.1)
Height (cm) 31 11,689 165.0 (7.0) 165.4 (6.7)
Race/ethnicity 27 10,020
Caucasian (including Russia
and Australia)
4217 (87.2%) 4562 (88%)
Asian 156 (3.2%) 157 (3%)
Afro-Caribbean 292 (6%) 292 (5.6%)
Central/South American 64 (1.3%) 67 (1.3%)
Middle Eastern (including
Iran and Turkey)
37 (0.8%) 37 (0.7%)
Other 68 (1.4%) 71 (1.4%)
Educational status of mother 29 8914
Low 724 (16.9%) 722 (15.6%)
Medium 1292 (30.2%) 1372 (29.6%)
High 2268 (52.9%) 2536 (54.8%)
Current smoker 29 10,958 865 (16.4%) 875 (15.4%)
Ex-smoker (pre-pregnancy) 13 4099 456 (23.8%) 523 (24%)
Adherence to intervention 18 3321 N/A 2022 (60.9%)
Parity 33 11,805
0 2692 (47.3%) 3027 (49.5%)
1 2083 (36.6%) 2136 (34.9%)
2 634 (11.1%) 647 (10.6%)
3 165 (2.9%) 179 (2.9%)
≥ 4 113 (2%) 129 (2.1%)
No exercise or sedentary 27 7583 1731 (47.6%) 1761 (44.6%)
Obesity (BMI of ≥ 30 kg/m2) 34 12,031 2434 (42.0%) 2680 (43.0%)
Previous macrosomia 8 2906 400 (29.1%) 390 (25.5%)
Previous GDM 11 4297 49 (2.4%) 60 (2.9%)
GDM 20 8256 14 (0.4%) 23 (0.6%)
DM 25 9589 9 (0.2%) 6 (0.1%)
Hypertension in pregnancy 20 5695 37 (1.3%) 47 (1.6%)
Hypertension 23 5494 54 (2.1%) 73 (2.5%)
N/A, not applicable.
a Percentage refers to proportion out of observations in control or intervention arms, respectively.
Reproduced from The International Weight Management in Pregnancy (i-WIP) Collaborative Group. Effect of diet and physical
activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual
participant data from randomised trials. BMJ 2017;358:j3119.1 This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original
work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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Risk of bias within eligible studies
Two-thirds (52/74, 70.3%) of eligible trials were rated as having a low risk of bias for random sequence
generation and selective reporting of outcomes. More than half of the studies (47/74, 63.5%) had
complete outcome data, with 18% of the remaining trials (13 studies) being rated as being at high risk of
bias. Allocation concealment was adequate in 45% (33/74) of included trials. In all studies the risk of bias
for blinding of participants and personnel was rated as either unclear (45/74, 60.8%) or high (29/74,
39.2%). In 27 studies (36.5%) there were no concerns over the rating of risk of bias for blinding of
outcome assessment, while 15 studies (20.3%) were assessed as being at high risk of bias. For the
remaining studies there was not enough information to assess the risk of bias (32/74, 43.2%). Figure 3
presents a summary of the risk of bias rating by domain for all eligible RCTs. The detailed assessment and
a global risk of bias are presented in Appendix 7.
TABLE 5 Details of outcome measures reported in all eligible studies that contributed to the IPD
Outcomes Number of studies Number of women
Baseline weight (kg) 33 11,748
Follow-up weight (kg) 33 9326
Change in weight (kg) 33 9320
Baseline BMI 34 12,031
Follow-up BMI 31 9240
Change in BMI 31 9238
PE 20 8350
PIH 25 9065
PE or PIHa 27 9915
GDMa 30 9882
Preterm delivery (< 37 weeks’ gestational age)a 34 11,731
All Caesarean sectiona 33 11,585
Emergency Caesarean section 16 7226
Elective Caesarean section 16 7226
Caesarean section unspecified 17 4423
Maternal composite outcome 24 8852
IUDa 22 9354
SGAa 34 11,682
LGAa 36 12,078
Admission to the NICUa 21 8749
Fetal/neonatal composite outcome 19 8239
a Components of the composite outcome.
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Quality assessment of studies that contributed data to individual
participant data meta-analysis
Studies that contributed IPD were rated as being at low risk of bias for random sequence generation (94%
vs. 47% among studies with unavailable IPD), allocation concealment (64% vs. 26%) and completeness of
outcome data (78% vs. 50%) compared with non-IPD studies. The risk-of-bias rating was similar in both
groups for selective reporting of outcomes (Table 6).
0 20 40 60
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80 100
Random sequence generation
Allocation concealment
Blinding of participants and personnel
Blinding outcome assessment
Incomplete outcome data
Selective reporting
52
33
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27
47
52
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38
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32
14
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15
13
12
Low risk
Unclear risk
High risk
FIGURE 3 Summary of the risk of bias rating for all eligible studies (n= 74).
TABLE 6 Risk-of-bias assessment in IPD studies compared with non-IPD
Items
Risk-of-bias rating, n (%)
Low Unclear High
IPD Non-IPD IPD Non-IPD IPD Non-IPD
Random sequence generation 34 (94) 18 (47) 2 (6) 18 (47) 0 (0) 2 (5)
Allocation concealment 23 (64) 10 (26) 11 (31) 27 (71) 2 (6) 1 (3)
Blinding of participants and personnel 0 (0) 0 (0) 17 (47) 28 (74) 19 (53) 10 (26)
Blinding of outcome assessment 16 (44) 11 (29) 6 (17) 26 (68) 14 (39) 1 (3)
Incomplete outcome data 28 (78) 19 (50) 3 (8) 11 (29) 5 (14) 8 (21)
Selective reporting of outcomes 23 (64) 29 (76) 6 (17) 4 (11) 7 (19) 5 (13)
Total number of studies 36 38 36 38 36 38
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Chapter 5 Effect of diet- and physical
activity-based interventions in pregnancy on maternal
and fetal outcomes
Gestational weight gain
Overall effect
Overall, diet- and physical activity-based interventions (33 studies, 9320 women) reduced GWG by an
average of –0.70 kg (95% CI –0.92 to –0.48 kg; I2 = 14.1%) (Figure 4), after accounting for baseline
weight and clustering effect.
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FIGURE 4 Effects of diet- and physical activity-based interventions on GWG (kg). Trt, treatment.
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All three individual interventions (diet, physical activity and mixed) had a similar effect on reducing GWG
by an average of 0.7 kg (Table 7).
Sensitivity analysis
The beneficial effect on GWG was consistent after including all available aggregate data from an
additional 27 non-IPD studies (MD –1.13 kg, 95% CI –1.58 to –0.68 kg) by including only IPD studies
that were rated as being at low risk of bias (MD –0.67 kg, 95% CI –0.95 to –0.38 kg), excluding women
non-adherent to the intervention (MD –0.76 kg, 95% CI –1.00 to –0.52 kg), restricting the IPD analysis to
women who were followed up until 37 weeks of gestation (MD –0.91 kg, 95% CI –1.17 to –0.66 kg) and
using BMI instead of maternal weight as a measure of weight change in pregnancy (MD –0.30 kg/m2,
95% CI –0.39 to –0.21 kg/m2) (see Appendix 8).
Differential effect of the intervention on gestational weight gain in
various subgroups
Thirty-one studies (9285 women) provided data to evaluate the differential effect of interventions on GWG
for women with varied BMI at booking. There was no significant treatment–covariate interaction for
baseline BMI (–0.02 kg change in effect per 1 kg/m2 increase in BMI, 95% CI –0.08 to 0.04 kg change).
We did not observe any interaction effect for other effect modifiers such as age (–0.03 kg change in effect
per 1-year increase in age, 95% CI –0.08 to 0.02 kg), parity (0.10 kg change in effect for multiparous vs.
nulliparous, 95% CI –0.39 to 0.60 kg change), ethnicity (0.05 kg change in effect for non-Caucasian vs.
Caucasian, 95% CI –1.27 to 1.37 kg change) and underlying medical condition (1.51 kg change in effect
for women with at least one condition vs. none, 95% CI –2.01 to 5.02 kg) (Table 8). The findings were
consistent when we analysed the continuous covariates as dichotomised measures.
Maternal outcomes
Overall effect
Diet- and physical activity-based interventions (24 studies, 8852 women) reduced the odds of adverse
maternal outcomes by 10% (summary OR 0.90, 95% CI 0.79 to 1.03; I2 = 26.7%). The effect was not
statistically significant at the 5% level (Figure 5).
The effects on composite maternal outcomes were evaluated in two-thirds of participants in studies of
mixed interventions, compared with 4% of participants in studies of diet-based interventions. The effects
of physical activity, diet and mixed approaches were not statistically significant (Table 9).
TABLE 7 Effects of diet- and physical activity-based interventions on GWG (kg)
Intervention
Number
of studies
Number
of women
Mean change of weight,
mean (SD) Summary-adjusted
MDa of weight
(95% CI) 95% PIControl Intervention
Diet 4 1168 11.0 (4.8) 10.2 (4.4) –0.72 (–1.48 to 0.04) –1.75 to 0.30
Physical activity 15 2915 10.8 (5.3) 9.8 (4.4) –0.73 (–1.11 to –0.34) –1.50 to 0.05
Mixed approach 15 5369 10.4 (5.7) 10.0 (5.8) –0.71 (–1.10 to –0.31) –1.42 to 0.01
Overallb 33 9320 10.8 (5.4) 10.1 (5.4) –0.70 (–0.92 to –0.48) –1.24 to –0.16
a Model accounting for baseline weight and clustering effect.
b The Renault et al.69 trial had two intervention arms (physical activity only and mixed approach).
Reproduced from The International Weight Management in Pregnancy (i-WIP) Collaborative Group. Effect of diet and physical
activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual
participant data from randomised trials. BMJ 2017;358:j3119.1 This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original
work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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TABLE 8 Subgroup effects and treatment–covariate interactions for GWG (kg)
Item
Number of
studies
Number of
women
Summary-adjusted
MDa of weight
(95% CI)
Summary
treatment–covariate
interaction (95% CI) 95% PI I2 (%)
Baseline BMI category
Normal weight 21 3376 –0.77 (–1.15 to –0.39) –1.68 to 0.14 33.9
Overweight 28 2574 –0.75 (–1.22 to –0.27) –2.07 to 0.58 32.7
Obese 31 3335 –0.85 (–1.41 to –0.29) –2.73 to 1.03 43.9
Per unit of BMI 31 9285 –0.02 (–0.08 to 0.04) –0.21 to 0.17 39.8
Overweight vs.
normal weight
21 6023 –0.11 (–0.77 to 0.55) –1.48 to 1.25 32.0
Obese vs. normal
weight
21 6023 0.06 (–0.90 to 1.01) –2.23 to 2.34 32.7
Obese vs. overweight 28 8802 –0.09 (–1.05 to 0.86) –3.2 to 3.01 46.9
Age
≥ 20 years 32 9045 –0.72 (–0.95 to –0.50) –1.29 to –0.15 17.0
< 20 years 13 232 0.05 (–1.34 to 1.44) –2.11 to 2.21 1.0
Per year of age 32 9277 –0.03 (–0.08 to 0.02) –0.14 to 0.09 25.9
< 20 vs. ≥ 20 years 13 5012 0.65 (–1.11 to 2.41) –2.66 to 3.97 10.8
Ethnicity
Caucasian 21 6814 –0.74 (–1.07 to –0.42) –1.52 to 0.04 41.4
Non-Caucasian 15 621 –0.42 (–1.12 to 0.28) –1.13 to 0.29 0.0
Non-Caucasian vs.
Caucasian
12 4439 0.05 (–1.27 to 1.37) –1.28 to 1.39 26.1
Parity
Nulliparous 27 4513 –0.80 (–1.17 to –0.43) –1.84 to 0.24 38.3
Multiparous 27 4548 –0.62 (–0.88 to –0.37) –0.88 to –0.37 0.0
Multiparous vs.
nulliparous
24 7247 0.10 (–0.39 to 0.60) –0.83 to 1.04 4.8
Pre-existing medical conditionb
No medical condition 18 4335 –0.62 (–0.90 to –0.34) –1.07 to –0.17 0.0
At least one medical
condition
6 128 0.40 (–1.92 to 2.71) –2.10 to 2.90 14.1
At least one medical
condition vs. none
5 1196 1.51 (–2.01 to 5.02) –4.13 to 7.15 28.4
a Model accounting for baseline weight and clustering effect.
b DM or hypertension.
Reproduced from The International Weight Management in Pregnancy (i-WIP) Collaborative Group. Effect of diet and physical
activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual
participant data from randomised trials. BMJ 2017;358:j3119.1 This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original
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FIGURE 5 Effects of diet- and physical activity-based interventions on composite maternal outcome. Trt, treatment.
TABLE 9 Effects of diet- and physical activity-based interventions on maternal composite outcome
Intervention
Number
of studies
Number
of women
Study arm (number of
events/total number of women)
Summary ORa
(95% CI) 95% PIControl Intervention
Diet 3 397 84/218 42/179 0.60 (0.20 to 1.75) 0.02 to 14.27
Physical activity 9 2311 367/1115 346/1196 0.81 (0.61 to 1.09) 0.48 to 1.37
Mixed approach 13 6259 1438/3009 1508/3250 0.97 (0.84 to 1.12) 0.82 to 1.13
Overallb 24 8852 1838/4226 1895/4624 0.90 (0.79 to 1.03) 0.68 to 1.20
a Model accounting for baseline weight and clustering effect.
b The Renault et al.69 trial had two intervention arms (physical activity only and mixed approach).
Reproduced from The International Weight Management in Pregnancy (i-WIP) Collaborative Group. Effect of diet and physical
activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual
participant data from randomised trials. BMJ 2017;358:j3119.1 This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original
work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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Sensitivity analysis by excluding studies rated as having a high risk of bias (summary OR 0.91, 95% CI 0.77
to 1.08) and women non-adherent to the intervention (summary OR 0.92, 95% CI 0.80 to 1.06) did not
affect the findings. The results of all sensitivity analyses are provided in Appendix 8.
Effect of interventions on individual maternal outcomes
The odds of Caesarean section were reduced by 9%, which bordered on statistical significance (summary
OR 0.91, 95% CI 0.83 to 0.99). For other maternal outcomes, such as GDM (OR 0.89, 95% CI 0.72 to
1.10), PE or PIH (OR 0.95, 95% CI 0.78 to 1.16), and preterm birth (OR 0.94, 95% CI 0.78 to 1.13), there
was a trend towards reduction that was not statistically significant. Meta-analysis based on published
aggregate data only showed a significant reduction in GDM (OR 0.78, 95% CI 0.64 to 0.95) and
Caesarean section (OR 0.90, 95% CI 0.82 to 0.99) compared with the control group. There were no
significant reductions in preterm birth (OR 0.80, 95% CI 0.63 to 1.01), PE or PIH (OR 0.89, 95% CI 0.75 to
1.05) (for details see Appendix 9). More participants were included in the IPD meta-analysis than in the
meta-analysis based on published data for outcomes preterm birth and PE or PIH; the participant numbers
were similar for GDM and Caesarean section (Table 10).
Differential effects of the intervention for composite maternal outcome in
various subgroups
Twenty-four studies (8848 women) contributed IPD to assess the differential effects of interventions
on the composite maternal outcome according to maternal BMI category. There was no significant
treatment–covariate interaction for baseline BMI (no change in effect for every 1-kg/m2 increase in BMI,
OR 95% CI 0.98 to 1.02). The effects of the interventions were not significantly modified by other relevant
covariates such as age (1% increase in effect for every 1-year increase in age, OR 95% CI 0.99 to 1.03),
parity (3% increase in effect for multiparity vs. nulliparity, OR 95% CI 0.75 to 1.39), ethnicity (7%
decrease in effect for non-Caucasian vs. Caucasian, OR 95% CI 0.63 to 1.37) and underlying medical
condition (44% increase in effect for women with none vs. at least one condition, OR 95% CI 0.15 to
13.74). The findings were consistent when continuous covariates were further analysed as categorical
values (Table 11).
TABLE 10 Intervention effects on the individual components of the composite maternal outcome: IPD
meta-analysis and aggregate data meta-analysis
Maternal outcome
Data
IPD (n= 36) Aggregate (n= 74)
Number
of studies
Number
of women
Summary ORa
(95% CI)
Number
of studies
Number
of women ORb (95% CI) I2 (%)
GDMc 27 9427 0.89
(0.72 to 1.10)
29 11,118 0.77
(0.63 to 0.94)
38
PE or PIH 22 9618 0.95
(0.78 to 1.16)
20 9198 0.89
(0.75 to 1.05)
0
Preterm birth 32 11676 0.94
(0.78 to 1.13)
23 7480 0.80
(0.63 to 1.01)
30
Caesarean section 32 11410 0.91
(0.83 to 0.99)
37 11,340 0.90
(0.82 to 0.99)
2
a IPD meta-analysis adjusted for clustering effect.
b Meta-analysis using aggregate published data, random-effect model.
c As defined in each study.
Reproduced from The International Weight Management in Pregnancy (i-WIP) Collaborative Group. Effect of diet and physical
activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual
participant data from randomised trials. BMJ 2017;358:j3119.1 This is an Open Access article distributed in accordance with
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Fetal/neonatal outcomes
Overall effect
Diet- and physical activity-based interventions (18 studies, 7981 women) did not reduce the odds of the
composite adverse fetal/neonatal outcome (summary OR 0.94, 95% CI 0.83 to 1.08) (Figure 6) after
adjusting for clustering.
TABLE 11 Subgroup effects and treatment–covariate interaction for composite maternal outcome
Item
Number
of studies
Number
of women
Summary ORa
(95% CI)
Summary
treatment–covariate
interaction (95% CI) 95% PI I2 (%)
Baseline BMI category
Normal weight 12 2445 0.91 (0.65 to 1.28) 0.42 to 1.96 48.5
Overweight 19 2222 1.04 (0.86 to 1.26) 0.86 to 1.26 0.0
Obese 20 4181 0.92 (0.80 to 1.05) 0.8 to 1.05 0.0
Per unit BMI 24 8848 1.00 (0.98 to 1.02) 0.98 to 1.02 0.0
Overweight vs. normal
weight
12 4040 1.02 (0.67 to 1.55) 0.52 to 1.99 20.2
Obese vs. normal weight 12 4040 0.95 (0.57 to 1.59) 0.57 to 1.60 0.0
Obese vs. overweight 20 7400 0.95 (0.71 to 1.26) 0.71 to 1.26 0.0
Age
≥ 20 years 24 8656 0.91 (0.81 to 1.02) 0.73 to 1.13 20.5
< 20 years 9 172 1.57 (0.66 to 3.71) 0.65 to 3.80 0.0
Per year of age 24 8828 1.01 (0.99 to 1.03) 0.99 to 1.03 0.0
< 20 years vs. ≥ 20 years 8 4720 1.84 (0.74 to 4.57) 0.72 to 4.72 0.0
Ethnicity
Caucasian 15 6510 0.92 (0.79 to 1.07) 0.67 to 1.25 26.8
Non-Caucasian 11 917 0.86 (0.63 to 1.17) 0.62 to 1.17 0.0
Non-Caucasian vs.
Caucasian
9 4851 0.93 (0.63 to 1.37) 0.62 to 1.38 0.0
Parity
Nulliparous 21 4613 0.87 (0.71 to 1.07) 0.54 to 1.41 39.8
Multiparous 22 4186 0.92 (0.78 to 1.07) 0.78 to 1.07 21.9
Multiparous vs. nulliparous 20 8053 1.03 (0.75 to 1.39) 0.53 to 2.00 34.0
Pre-existing medical conditionb
No medical condition 15 3135 0.85 (0.66 to 1.09) 0.46 to 1.57 42.5
At least one medical
condition
5 89 1.65 (0.36 to 7.51) 0.29 to 9.37 0.0
None vs. at least one
medical condition
4 916 1.44 (0.15 to 13.74) 0.03 to 76.75 24.9
a Model accounting for clustering effect.
b DM or hypertension.
Reproduced from The International Weight Management in Pregnancy (i-WIP) Collaborative Group. Effect of diet and physical
activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual
participant data from randomised trials. BMJ 2017;358:j3119.1 This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original
work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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Two studies (346 women) evaluated diet-based interventions, five (1274 women) assessed physical
activity-based interventions and 12 (6494 women) studied mixed interventions on composite fetal/neonatal
outcomes. None of the three interventions reduced composite adverse fetal/neonatal outcome (Table 12).
Differential effect of the intervention for composite fetal/neonatal outcome
in various subgroups
Eighteen studies (7981 women) provided IPD to assess the differential effects of interventions by maternal
baseline BMI on composite fetal/neonatal outcome. There was a 2% decrease in the treatment effect of
Exercise
Mixed
Intervention
Mixed
Exercise
Mixed
Mixed
Diet
Exercise
Diet
Mixed
Mixed
Mixed
Mixed
Mixed
Mixed
Mixed
Exercise (trt1) 
and mixed (trt2)
Exercise
Pooled effect overall
Stafne88 2012
Jeffries92 2009
Study
Sagedal94 2013
Khaledan83 2010
Luoto62 2011
Vinter70 2011
Khoury76 2005
Baciuk79 2008
Wolff71 2008
Petrella74 2014
Guelinckx66 2010
Rauh63 2013
Poston68 2015
Phelan93 2011
Dodd72 2014
Bogaerts64 2013
Renault69 2014
Oostdam75 2012
0.89 (0.62 to 1.28)
0.74 (0.43 to 1.28)
Odds ratio
(95% CI)
0.97 (0.67 to 1.41)
0.50 (0.11 to 2.38)
0.12 (0.73 to 1.71)
0.90 (0.55 to 1.46)
0.69 (0.40 to 1.19)
2.13 (0.76 to 5.96)
0.81 (0.23 to 2.93)
0.45 (0.14 to 1.47)
0.68 (0.31 to 1.48)
0.25 (0.37 to 1.96)
1.24 (0.99 to 1.56)
0.70 (0.43 to 1.12)
0.88 (0.72 to 1.08)
1.19 (0.60 to 2.35)
1.04 (0.65 to 1.65)
1.03 (0.38 to 2.80)
10.51
3.21
Weight (%)
7.33
0.49
4.90
3.80
0.94 (0.83 to 1.08) 100.00
3.60
0.86
0.74
0.73
2.22
2.89
19.05
4.69
26.78
2.44
5.00
0.78
Favours intervention Favours control 
1.0
Odds ratio
0.1 0.3 3.0 10.0
FIGURE 6 Effect of diet- and physical activity-based interventions on composite fetal/neonatal outcome.
TABLE 12 Effects of diet- and physical activity-based interventions on composite fetal/neonatal outcome
Intervention
Number
of studies
Number
of women
Study arm (number of
events/total number of women)
Summary-adjusted
ORa (95% CI) 95% PIControl Intervention
Diet 2 346 47/181 31/167 0.64 (0.02 to 18.06) –
Physical activity 5 1274 156/641 170/634 1.23 (0.72 to 2.10) 0.45 to 3.32
Mixed 12 6494 875/3338 953/3626 1.02 (0.90 to 1.15) 0.87 to 1.19
Overallb 18 7981 951/3802 1007/4179 0.94 (0.83 to 1.08) 0.74 to 1.21
a Model accounting for clustering effect.
b The Renault et al.69 trial had two intervention arms (physical activity only and mixed approach).
Reproduced from The International Weight Management in Pregnancy (i-WIP) Collaborative Group. Effect of diet and physical
activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual
participant data from randomised trials. BMJ 2017;358:j3119.1 This is an Open Access article distributed in accordance with
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borderline significance for every 1 kg/m2 increase in booking BMI for composite fetal/neonatal outcomes
(OR 0.98, 95% CI 0.95 to 1.00). There was no treatment–covariate interaction for other variables, such
as maternal age of < 20 years (OR 1.05, 95% CI 0.33 to 3.35), ethnicity (12% decrease in effect for
non-Caucasian vs. Caucasian, 95% CI 0.75 to 1.68), parity (6% reduction in effect for multiparous vs.
nulliparous, 95% CI 0.64 to 1.47), baseline medical conditions (42% increase in effect for women with at
least one medical condition vs. none, 95% CI 0.00 to 2440.15) (Table 13).
TABLE 13 Subgroup effects and treatment–covariate interaction for fetal/neonatal composite outcome
Item
Number
of studies
Number
of women
Summary ORa
(95% CI)
Summary
treatment–covariate
interaction (95% CI) 95% PI I2 (%)
Baseline BMI category
Normal weight 7 1843 0.93 (0.60 to 1.43) 0.40 to 2.16 31.6
Overweight 12 2065 0.83 (0.61 to 1.13) 0.49 to 1.39 0.0
Obese 13 4327 0.92 (0.72 to 1.19) 0.55 to 1.54 29.7
Per unit BMI 18 7978 0.98 (0.95 to 1.00) 0.94 to 1.02 18.5
Overweight vs. normal
weight
8 2827 0.87 (0.40 to 1.92) 0.15 to 4.91 44.0
Obese vs. normal weight 8 2827 0.84 (0.42 to 1.66) 0.41 to 1.70 0.0
Obese vs. overweight 14 6272 0.94 (0.60 to 1.45) 0.51 to 1.71 0.0
Age
≥ 20 years 16 8061 0.95 (0.82 to 1.09) 0.72 to 1.24 0.0
< 20 years 7 162 1.01 (0.34 to 2.98) 0.32 to 3.14 0.0
Per year of age 18 7965 1.01 (0.98 to 1.04) 0.97 to 1.05 4.1
< 20 vs. ≥ 20 years 6 4941 1.05 (0.33 to 3.35) 0.30 to 3.67 0.0
Ethnicity
Caucasian 11 6018 0.93 (0.79 to 1.08) 0.75 to 1.14 3.5
Non-Caucasian 9 939 1.10 (0.78 to 1.54) 0.78 to 1.55 0.0
Non-Caucasian vs. Caucasian 9 5146 1.12 (0.75 to 1.68) 0.74 to 1.69 0.0
Parity
Nulliparous 16 4152 0.97 (0.80 to 1.17) 0.69 to 1.35 21.1
Multiparous 15 4048 0.91 (0.72 to 1.15) 0.56 to 1.48 23.2
Multiparous vs. nulliparous 15 7295 0.94 (0.64 to 1.37) 0.39 to 2.28 35.5
Pre-existing medical conditionb
No medical condition 12 3407 0.89 (0.74 to 1.08) 0.74 to 1.08 0.0
At least one medical
condition
3 63 0.54 (0.04 to 7.52) 0.00 to 1285.09 0.0
At least one medical
condition vs. none
3 925 0.58 (0.03 to 9.81) 0.00 to 2440.15 0.0
a Model accounting for clustering effect.
b DM or hypertension.
Reproduced from The International Weight Management in Pregnancy (i-WIP) Collaborative Group. Effect of diet and physical
activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual
participant data from randomised trials. BMJ 2017;358:j3119.1 This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original
work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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None of the sensitivity analyses performed showed a significant impact on the intervention effect
(see Appendix 8).
Effect of interventions on individual fetal/neonatal outcomes
Compared with published aggregate data, IPD were available for more participants for fetal/neonatal
outcomes, such as SG, LGA and admission to the NICU. IPD meta-analysis did not show a significant
effect on SGA infants (summary OR 1.06, 95% CI 0.94 to 1.20), LGA infants (summary OR 0.90,
95% CI 0.76 to 1.07) or admission to the NICU (summary OR 1.01, 95% CI 0.84 to 1.23). Aggregate
meta-analysis of published data showed similar results of no effect for all fetal outcomes (Table 14).
Publication bias
The contour-enhanced funnel plots on small-study effects (potential publication bias) for GWG (Figure 7)
showed visual and statistical evidence (Egger’s test, p = 0.038) of asymmetry, indicating that smaller
studies were more likely to have large intervention effects. Addition of aggregate data from non-IPD
studies to the meta-analysis worsened the symmetry, suggesting that the asymmetry was not caused by
availability bias. Exclusion of studies rated as being at high risk of bias to the analysis improved symmetry
substantially (Egger’s test, p = 0.608).
There was significant evidence of small-study effects for the composite maternal (Peter’s test, p = 0.036),
but not for the fetal/neonatal composite outcome (p = 0.398) (Figure 8). Heterogeneity, which was present
in all these meta-analyses, might be the cause (rather than publication bias) of asymmetry in the
funnel plots.
TABLE 14 Intervention effects on the individual components of the composite fetal and neonatal outcome:
IPD meta-analysis and aggregate meta-analysis
Fetal/neonatal
outcome
Data
IPD (n= 35 studies) Aggregate (n= 74 studies)
Number
of studies
Number
of women
Summary ORa
(95% CI)
Number
of studies
Number
of women
Summary ORb
(95% CI) I2 (%)
IUDc – – – 4 4857 1.95
(0.55 to 6.90)
0
SGA 33 11,666 1.06
(0.94 to 1.20)
8 2835 1.27
(0.91 to 1.77)
0
LGA 34 12,047 0.90
(0.76 to 1.07)
13 5827 0.88
(0.68 to 1.15)
37
Admission to
the NICU
16 8140 1.01
(0.84 to 1.23)
6 5200 0.95
(0.77 to 1.19)
22
a Model accounting for baseline weight and clustering effect.
b Aggregate meta-analysis using published data.
c Insufficient data.
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FIGURE 7 Contour-enhanced funnel plot for GWG. (a) IPD data only; (b) IPD and aggregate data; and (c) IPD
studies classified as being at low risk of bias.
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FIGURE 8 Contour-enhanced funnel plot for (a) composite maternal; and (b) fetal/neonatal outcomes.
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Chapter 6 Association of maternal weight and
weight gain in pregnancy and pregnancy complications
Gestational weight gain, maternal weight at booking and adverse
maternal and fetal/neonatal outcomes
Twenty-three trials evaluated the association of GWG, BMI at booking and composite maternal outcomes
(3367 women), and 19 trials provided data for composite fetal/neonatal outcomes (3030 women) from
women in control groups. There was no association between GWG, booking BMI and risk of adverse maternal
(OR 1.03, 95% CI 0.93 to 1.15) or fetal/neonatal complications (OR 1.02, 95% CI 0.91 to 1.15), and this
effect does not differ by baseline BMI (Table 15).
Figure 9 presents the relationship between presence or absence of adverse maternal and fetal
complications for women entering pregnancy with varied BMI, for different values of GWG.
Adherence to the Institute of Medicine’s recommendations and
risk of adverse pregnancy outcomes
In women who were normal weight at booking, about 40% adhered to the IOM’s recommendations and
gained up to 16 kg in pregnancy; another 40% gained less than the recommended range, and less than
one-fifth exceeded the recommendations. One-third (29%) of overweight and obese (30%) women
complied with the recommendations. About half of overweight women and 44% of obese women
exceeded the recommended ranges (Table 16).
The odds of adverse composite outcome were not significant when normal weight women gained
above (summary OR 1.05, 95% CI 0.60, 1.82) and below (summary OR 0.99, 95% CI 0.67, 1.47) the
recommended targets. We did not observe any significant additional increase in maternal risks when obese
and overweight women did not comply with the recommended targets (Table 17). There was no significant
increase in the odds of adverse maternal outcomes in overweight and obese women who gained below or
above the recommendations.
TABLE 15 Effect of GWG on composite maternal and fetal/neonatal outcomes accounting for the modifying effect
of baseline BMI category
Outcomes
Number of
studies
Number of
women
Effect of GWG,
ORa (95% CI)
Modifying effect
of baseline BMI,
OR (95% CI) I2 (%)
Composite maternal outcome 23 3367 1.03 (0.93 to 1.15) N/Ab 0
Composite fetal and neonatal
outcome
19 3030 1.02 (0.91 to 1.15) 1.00 (1.00 to 1.00) 0
N/A, not available.
a Model accounting for clustering effect and for interaction between baseline BMI and GWG.
b Non-convergence during second step of the meta-analysis.
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TABLE 16 Adherence to IOM’s guidelines by baseline BMI category
GWG Normal weight, n (%) Overweight, n (%) Obese, n (%)
Below IOM 649 (40) 242 (19) 400 (26)
Adherent to IOM 663 (41) 362 (29) 467 (30)
Exceeds IOM 310 (19) 641 (51) 695 (44)
Total 1622 1245 1562
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FIGURE 9 Scatterplot of GWG against baseline BMI for adverse (a) maternal; and (b) fetal/neonatal composite outcomes.
TABLE 17 Association between adherence to the IOM-recommended weight-gain targets in pregnancy and
composite adverse maternal events within subgroups of BMI category
Adherence to IOM’s
targets in pregnancy
Number of
studies
Number of
women
Summary ORa
(95% CI) 95% PI I2 (%)
Normal weight
Below vs. adherent 12 1092 0.99 (0.67 to 1.46) 0.67 to 1.46 0.0
Exceeds vs. adherent 11 1083 1.05 (0.61 to 1.80) 0.41 to 2.65 0.0
Overweight
Below vs. adherent 16 889 1.28 (0.79 to 2.08) 0.79 to 2.08 0.0
Exceeds vs. adherent 18 904 0.78 (0.49 to 1.26) 0.34 to 1.80 0.0
Obese
Below vs. adherent 17 1261 1.38 (0.95 to 2.01) 0.88 to 2.18 0.0
Exceeds vs. adherent 19 1324 1.15 (0.85 to 1.56) 0.85 to 1.56 0.0
a Model adjusted for clustering effect.
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Non-adherence to IOM’s targets for weight gain in pregnancy did not pose additional risks of fetal
complications in normal weight, overweight and obese pregnant women (Table 18). The odds of
composite adverse fetal outcomes were not significantly increased in normal weight, overweight and
obese women who gained more or less than the recommended targets.
TABLE 18 Association between adherence to IOM’s guidelines and composite adverse fetal events within
subgroups of BMI
Adherence to the IOM-recommended
weight-gain targets in pregnancy
Number of
studies
Number of
women
Summary ORa
(95% CI) 95% PI I2 (%)
Normal weight
Below vs. adherent 9 821 0.87 (0.40 to 1.90) 0.16 to 4.84 38.4
Exceeds vs. adherent 9 821 1.26 (0.60 to 2.65) 0.35 to 4.57 29.0
Overweight
Below vs. adherent 10 830 1.07 (0.51 to 2.22) 0.38 to 2.99 0.0
Exceeds vs. adherent 10 830 1.09 (0.68 to 1.74) 0.67 to 1.76 0.0
Obese
Below vs. adherent 16 1285 1.57 (1.05 to 2.32) 1.05 to 2.33 0.0
Exceeds vs. adherent 15 1271 1.36 (0.89 to 2.06) 0.67 to 2.75 0.0
a Model adjusted for clustering effect.
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Chapter 7 Predictors of gestational weight gain
Maternal characteristics, such as increase in age and parity, showed a significant association withreduced GWG, on average, by 0.09 kg (95% CI –0.12 to –0.06 kg) and 0.51 kg (95% CI –0.78 to
–0.24 kg), respectively, in univariate (crude) meta-analyses. Non-Caucasian ethnicity was a significant
predictor of decreased weight gain (summary-adjusted difference –0.89 kg, 95% CI –1.76 to –0.02 kg).
Other maternal characteristics (such as smoking, pre-existing medical conditions, baseline physical activity
and maternal education) were not associated with weight gain in pregnancy (Table 19).
Multivariable analysis showed that increase in maternal age (–0.1 kg, 95% CI –0.14 to –0.06 kg) and
multiparity (–0.73 kg, 95% CI –1.24 to –0.23 kg) were associated with significantly reduced GWG.
The details of the multivariable analysis for the association between baseline characteristics and GWG are
provided in Table 20.
TABLE 19 Univariate analysis of predictors of GWG (kg)
Baseline characteristic
Number of
studies
Sample
size
Crude summary-adjusted
differencea in GWG
(95% CI) 95% PI I2 (%)
Age (years) 32 4424 –0.09 (–0.12 to –0.06) –0.12 to –0.06 14.7
Non-Caucasian vs. Caucasian 13 2101 –0.89 (–1.76 to –0.02) –1.83 to 0.05 18.7
Pooled effect ethnicity (reference category: Caucasian)
Asian 7 1758 –0.53 (–2.24 to 1.18) –3.42 to 2.36 21.4
Afro-Caribbean 9 1822 –1.17 (–2.65 to 0.30) –2.69 to 0.34 0.0
Central/South American 1 110 – – –
Middle Eastern 4 289 –1.35 (–7.12 to 4.42) –9.16 to 6.46 0.0
GDM 2 532 –1.43 (–16.58 to 13.72) – 0.0
DM 3 305 –1.70 (–8.25 to 4.84) –21.02 to 17.62 0.0
PIH 3 539 –2.08 (–13.71 to 9.55) –65.15 to 61.00 80.4
Chronic hypertension 5 546 –1.43 (–4.80 to 1.95) –8.81 to 5.96 52.8
Current smoker 21 3572 –0.07 (–0.98 to 0.84) –2.39 to 2.25 47.4
Parity (number) 27 3673 –0.51 (–0.78 to –0.24) –1.42 to 0.40 56.8
Multiparous vs. nulliparous 25b 3427 –1.12 (–1.55 to –0.69) –2.30 to 0.07 32.4
Maternal education (reference category: low)
Medium 23 3030 0.16 (–0.35 to 0.68) –0.35 to 0.68 0.0
High 23 3030 –0.09 (–0.71 to 0.53) –0.71 to 0.53 23.8
Some physical activity vs.
physically inactive
22 2697 –0.30 (–0.70 to 0.10) –0.71 to 0.53 23.8
a Model adjusted for baseline weight and clustering effect.
b Two studies (Harrison et al.73 and Vítolo et al.77) include only multiparous women and are therefore excluded from
this analysis.
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TABLE 20 Multivariable analysis of maternal characteristics and GWG (kg)
Baseline characteristic
Number of
studies
Sample
size
Crude summary-adjusted
differencea in GWG
(95% CI) 95% PI I2 (%)
Age (years) 17 2414 –0.10 (–0.14 to –0.06) –0.14 to –0.06 0.0
Ethnicity: non-Caucasian vs. Caucasian 10 1105 –0.11 (–1.53 to 1.32) –3.12 to 2.91 34.6
Current smoker 13 2075 –0.06 (–1.65 to 1.52) –3.93 to 3.81 57.1
Multiparous vs. nulliparous 15 2120 –0.73 (–1.24 to –0.23) –1.83 to 0.36 15.3
Maternal education (reference category: low)
Medium 15 2307 –0.07 (–0.91 to 0.77) –1.88 to 1.74 27.6
High 15 2307 –0.18 (–1.18 to 0.81) –2.57 to 2.21 36.3
Some physical activity vs. inactive 17 2414 –0.26 (–0.63 to 0.11) –0.63 to 0.11 0.0
a Model accounting for baseline weight and clustering effect.
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Chapter 8 Economic evaluation and
decision-analytic modelling
Objectives
The main objective of this model-based economic evaluation was to determine the cost-effectiveness of
diet- and exercise-based interventions in pregnancy to improve maternal and fetal clinical outcomes
compared with usual care, using the results of the IPD meta-analysis for all women. A secondary objective
was to compare the cost-effectiveness of the intervention for women whose pre-pregnancy weight was
classed as normal, overweight or obese. The success of any intervention in supporting women to achieve
optimum weight gain during pregnancy needs to be balanced against the resources required to achieve
this outcome, and additional costs must be assessed in terms of any additional benefits that can be
attributed to them.95 Identification of specific subgroups of women in whom the intervention is
cost-effective has the potential to target interventions to particular groups.
Methods
In the economic analysis, diet- and physical activity-based interventions in pregnancy were compared with
care as usual (control). The principal clinical data used to populate the model were drawn from the IPD
meta-analyses (see Chapter 5); this was supplemented with data from other published sources. Resource
use was estimated from the published evidence and unit costs were based on published sources such
as the Unit Costs of Health and Social Care 201496 and the National Schedule of Reference Costs:
The Main Schedule.97
Model structure
The appropriate model for this study was a decision tree because of the short-term nature of the decision
problem.98 The model was developed using TreeAge Pro 2014 software (TreeAge Software, Inc.,
Williamstown, MA, USA). The structure was informed by the objectives of the study, the pathways indicated
by the data and trials included in the IPD meta-analysis, clinical input, NICE guidelines on the management
of women in pregnancy10,99,100 and the approaches adopted in previously published model-based economic
evaluations in relevant clinical areas.101–105 For completeness, the model included all the potential pathways
that could be followed by the women. Women entered the model at the point of randomisation to receive
the intervention or care as usual (control). All women were assumed to follow one of six clinical pathways
based on whether or not they developed pregnancy-related complications or experienced miscarriage or
maternal death. These pathways were (1) PE, (2) GDM, (3) PIH, (4) no complication, (5) second-trimester
miscarriage and (6) maternal death (Figure 10). Each pathway included appropriate maternal and fetal
outcomes as detailed below.
For the base case, outcomes were considered until the point of discharge from hospital. Once women
entered the model, it was assumed that they followed one of the clinical pathways defined in the model,
based on whether or not they developed a pregnancy-related condition/complication. Complications
were defined in accordance with the definitions used in studies included in the IPD meta-analysis. To
illustrate the approach used for each patient pathway, a subset of the model is presented for the PE
pathway (Figure 11). Women who developed more than one complication were allocated to the most
resource-intensive pathway based on an analysis of NICE clinical pathways and clinical opinion.106 The
intensity of pathways was defined as follows (in decreasing order of intensity): (1) PE, (2) GDM99 and
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(3) PIH.100 For the purposes of the model it was assumed that once women developed a complication they
were treated in accordance with NICE guidelines and incurred associated antenatal health-care costs.
Women who did not develop any of the specified conditions were assumed to receive routine antenatal
care only. It was assumed that routine antenatal care would be received by all women, irrespective of
whether or not they developed a pregnancy-related condition.107 As the purpose of economic evaluation is
to examine the differences in costs and outcomes between alternative courses of action,95 the costs of
routine antenatal care were not included in the model as they would be identical for each arm.
For all clinical pathways, women could either experience a preterm delivery or a delivery at term; preterm
delivery was defined as delivery before 37 gestational weeks.108 Three types of delivery were included in
the model: Caesarean section, assisted delivery and vaginal delivery. The outcome of the delivery was
either a stillbirth (or IUD) or live baby. Stillbirth was defined as a baby born with no signs of life after
24 weeks of completed pregnancy and IUD as a baby with no signs of life in utero.109 Women who
experienced stillbirth and IUD were assumed to have received appropriate antenatal care for any condition
they were recorded as developing during the trial. Additional costs associated with investigations and
counselling were included in the total costs for these women.110
The model also included pathways for second-trimester miscarriage and maternal death in order to reflect
all possible pathways for the women. Second-trimester miscarriage was defined as the spontaneous loss
of pregnancy after the 14th week of pregnancy and before the 24 completed weeks. 111 The risk of
second-trimester miscarriage and maternal death was based on secondary sources and applied to both
arms equally to preserve the face validity of the model.112 As the purpose of the economic evaluation was
i-WIP study
Intervention
PE
GDM
PIH
No complications
Second-trimester
miscarriage
Maternal death
Usual care
FIGURE 10 Patient pathways incorporated in the model.
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to examine the differences in costs and outcomes between the intervention and control arms, costs were
not included for second-trimester miscarriage and maternal death, as they would be identical for each arm.
Model assumptions
To carry out the model-based analysis some further assumptions were required. These are
presented below.
Pre-eclampsia pathway
A number of assumptions were made for the PE pathway based on NICE guidelines100 and the findings of
a systematic review that was carried out for this report (see Appendix 10 for further details). NICE
guidance states that before 37 weeks delivery should not be recommended for women with PE unless
severe or refractory hypertension is present. In women with PE with mild and moderate hypertension, the
offer of delivery will depend on maternal and fetal condition, risk factors and the availability of neonatal
intensive care. A systematic review was conducted to identify studies that had considered the costs
associated with hypertensive disorders in pregnancy (see Appendix 10 for further details). Five studies were
identified that included primary data on the costs associated with PE in pregnancy.113–117 Only one study
collected primary data on resource use for women who were primarily diagnosed with PE and who were
undergoing expectant monitoring.113 This study was a RCT that compared expectant monitoring and
immediate delivery for women with hypertensive disorders between 34 and 37 weeks of gestation [the
Hypertension and Pre-eclampsia Intervention Trial At near Term (HYPITAT-II)]. The majority of the women
included in the trial had PE (47%) or superimposed PE (13%). The findings of this study were used to
inform the modelling of the PE pathway and the following assumptions were made:
l Women develop PE and give birth between 34 and 37 weeks of gestation to reflect the findings of the
HYPITAT II study. Other evidence suggests that only a minority of women would give birth before this
period; for example, a large clinical trial in this area118 found that 82% of women with PE gave birth
after 34 weeks.
l All women receive expectant monitoring for their condition, in line with NICE guidance.114
l Antenatal care was as reported in the HYPITAT-II study. This included maternal admissions,
cardiotocography and ultrasounds, outpatient visits, laboratory tests and medication.113
l Data from the IPD were used to estimate the timing and type of delivery. The cost of care in the
intrapartum phase was estimated using nationally reported average costs. It was assumed that because
the women were diagnosed with PE and hypertension that all types of delivery would have a
‘complications and comorbidities’ score of 2.119
l Women receive the postnatal care that was reported in the HYPITAT-II study. This included maternal
admissions, neonatal admission, extra care and transfers.113
l The costs included in the analysis were a conservative estimate of the costs associated with PE
during pregnancy, and the uncertainty around this estimate was explored in the sensitivity analysis
(particularly around the inclusion of costs associated with early-onset PE, that is disease occurring
before 34 weeks).
Gestational diabetes mellitus pathway
The following assumptions were made for the GDM pathway based on NICE guidelines99 and a systematic
review of the literature conducted for this report. The systematic review identified 10 studies that were
concerned with costs and resource use for women with GDM. Only one RCT that recorded primary
health-care resource use for women who were diagnosed with GDM was identified.120 This study included
all costs incurred from the start of pregnancy until the final discharge of the mother and her child(ren).
As routine antenatal care was included in the costs reported by the economic evaluation of the RCT,
the estimate for the cost of antenatal care was based on the results of a modelling study produced to
inform the development of for NICE guidelines on DM in pregnancy.99 This cost was estimated from
guideline recommendations for the treatment of women with GDM. The costs associated with delivery
were based on national average costs reported in the UK. The costs associated with postnatal care of the
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mother and infant were based on the health-care costs reported in the economic analysis conducted
alongside the RCT.120 The following assumptions were made for women with GDM:
l All women were initially treated with diet. After 10 days, if this treatment was not successful, women
received insulin treatment (64% patients).
l Health-care professionals instructed women how to undertake self-monitoring of blood glucose levels,
provided dietary advice, assessed the success of diet treatment and instructed women who required
insulin treatment on this treatment.
l Estimates of the timing and type of delivery were based on data from the IPD. The cost of care in the
intrapartum phase reflects nationally reported costs. As women had a diagnosis of GDM, all types of
delivery had a complications and comorbidities score of 1.119
l The costs of postnatal care were as reported in an economic evaluation undertaken along a RCT.120
This included NICU costs and costs associated with hospital care following delivery (all of the neonatal
care costs and half of the non-delivery hospitalisation costs were incurred after the birth).
Pregnancy-induced hypertension pathway
A number of assumptions were made for the gestational hypertension pathway based on NICE guidelines
and the results of a systematic review conducted to inform this report (see Appendix 10). For women with
gestational hypertension, delivery of the infant should not be offered before 37 weeks and after this point
the timing of, and maternal and fetal indications for, birth should be agreed between the woman and senior
obstetrician.114 The systematic review identified very few studies that were concerned with the resource
use associated with the expectant monitoring of women with gestational hypertension (without PE) in line
with this guidance. An economic evaluation was identified that included costs associated with expectant
monitoring for women with hypertensive disorders (the HYPITAT-I117). This trial involved a majority of women
with gestational hypertension only (65%).121 The systematic review also identified an economic model
developed to support NICE guidelines that was concerned with immediate birth compared with expectant
management in women with mild to moderate gestational hypertension after 37 weeks of gestation.100
However, the model used secondary data and did not involve primary cost collection.
l For the purposes of simplification, it was assumed that women developed gestational hypertension
after 37 weeks, as most hypertensive disorders present after 36 weeks of gestation.121
l Antenatal care was assumed to follow that recorded in the HYPITAT-I study and included maternal
admission, home care, cardiotocography, ultrasound, outpatient visits, assessments, laboratory tests
and medication.117
l The findings of the IPD meta-analysis were used to estimate the timing and mode of delivery for
women with PIH. National data on costs were used to estimate the cost of intrapartum care. Because
all women had a diagnosis of hypertension, it was assumed that all types of birth would have a
complications and comorbidities score of 1.119
l In the postnatal period, just 2% of women were assumed to receive intensive care, while 90% were
admitted to the maternity ward for a mean period of 3.4 days. In addition, 3% of infants were
assumed to be admitted to the NICU, and 19% to receive medium-level care on the maternal ward,
in line with findings from the HYPITAT–I trial.117
No complications
A series of assumptions were made for the pathway followed by women who did not develop
complications during pregnancy, based on an analysis of NICE guidance:107
l Women who did not develop any complications received routine antenatal care only.
l The estimate of the timing and mode of delivery was based on the findings of the IPD meta-analysis.
For the purpose of simplification, this means that women would not have any complications and that
their delivery would have a complications and comorbidities score of 0.119
l Women with no complications would not receive any additional postnatal care.
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l The findings of the IPD meta-analysis were used to estimate the probability that infants in this arm would
be admitted to the NICU. The findings of a study that reported average length of stay in the NICU by
gestational age were used to estimate the length of stay for infants who were born preterm and at term.119
Clinical data
The primary focus of the economic evaluation was the effect of the intervention on adverse maternal and
fetal outcomes. The maternal outcomes included the development of three pregnancy-related conditions
(PE, GDM and PIH), as well as outcomes relating to the timing and mode of delivery (preterm delivery and
Caesarean section). Fetal outcomes included IUD, SGA, LGA and admission to the NICU.
Maternal outcomes
The estimates of baseline risk and the effect of the intervention on the development of pregnancy-related
conditions were drawn from the IPD meta-analysis. This is shown in Table 21. For the intervention effect,
data from the IPD meta-analysis were used to estimate pooled effect ORs for the development of PE,
GDM and PIH. A two-stage process was used using a REML approach, and CIs were corrected using the
Knapp–Hartung correction. The baseline risk for the usual-care group was based on pooled data for
the control groups included in the trials. Maternal outcomes were not considered when they were already
observed at baseline, that is, we did not count the presence of GDM in women who had DM or GDM at
baseline and we did not count PIH in women who had PIH at baseline. The estimate of the risk of second
semester miscarriage was based on a review article that summarised evidence on the epidemiology of
miscarriage.122 Data on the risk of maternal death were drawn from the findings of the confidential
enquiry into maternal mortality and morbidity in the UK and Ireland 2009–12.123
The IPD meta-analysis also considered maternal outcomes that related to the timing and type of delivery
(Table 22). This included preterm delivery, normal delivery, assisted delivery and Caesarean section.
Delivery-related outcomes were estimated for all women with a pregnancy-related condition and for
women with no condition (irrespective of whether they received the intervention or care as usual). Women
with no complications were defined as those not reported as having PE, GDM or PIH, with at least one of
these conditions being reported in the trial. Women were excluded from the analysis if missing data for all
of these three outcomes were missing.
TABLE 21 Baseline risk and intervention effect (development of pregnancy-related conditions)
Description Base-case value Distribution and values Source
Baseline risk of PE 0.05 Beta(199, 3786) IPD
Baseline risk of GDM 0.114 Beta(542, 4205) IPD
Baseline risk of PIH 0.043 Beta(187, 4133) IPD
Baseline risk of no complications 0.793 Remainder from above IPD
OR for PE 0.99 Log-normal(0.79 to 1.24) IPD
OR for GDM 0.89 Log-normal(0.72 to 1.10) IPD
OR for PIH 0.93 Log-normal(0.69 to 1.25) IPD
Risk of second-trimester miscarriage 0.01 Beta(1, 99) Regan and Rai122
Risk of maternal death 0.00010 Beta(10, 99,990) Knight et al.123
Note
Values of α and β are given for beta distributions, and 95% confidence limits for log-normal distributions. The base-case
values were used to produce deterministic results. The distributions were used to undertake probabilistic sensitivity analysis,
produce the probabilistic results and produce the incremental cost-effectiveness scatterplots.
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Fetal outcomes
Data from the IPD were used to estimate fetal and infant outcomes for all women with a pregnancy-
related condition and for women with no condition recorded (irrespective of whether they received the
intervention or care as usual). Women were defined as having no pregnancy-related condition if they were
not reported as having PE, GDM or PIH, with at least one of these conditions being reported in the trial.
Women were excluded from the analysis if data were missing for all of these three outcomes. Table 23
shows fetal outcomes for women by pregnancy-related condition/no condition.
Cost data
The cost components of the decision model were parameterised with data from NHS reference costs
2013/1497 and other secondary sources. Costs were calculated in 2013–14 GBP. Costs from secondary
sources were inflated to 2013–14 prices using the hospital and community health services pay and prices
index.96 When necessary, costs were converted to GBP using historical annual average rates124 and then
inflated to 2013–14 prices.
The estimate of the cost of the weight management intervention was based on the results of a systematic
review of economic evaluations of weight management interventions in pregnancy that was conducted
for this report (see Appendix 10). The review identified 11 studies that were concerned with the
cost-effectiveness of weight management interventions during pregnancy.68,101,125–133 Four of these involved
women who already had DM or GDM and hence the intervention costs included additional monitoring
and medication.125,130,131,133 Two did not report a cost for an intervention.101,126 Data on the cost of the
TABLE 22 Timing and mode of delivery for women
Description Base-case value Distribution and values Source
Preterm delivery in women with PE 0.234 Beta(92, 302) IPD
Preterm delivery in women with GDM 0.076 Beta(82, 1003) IPD
Preterm delivery in women with PIH 0.049 Beta(19, 366) IPD
Preterm delivery in women with no complications 0.104 Beta(193, 1671) IPD
Caesarean section in women with PE 0.46 Beta(180, 211) IPD
Assisted delivery in women with PE 0.11 Beta(43, 348) IPD
Normal delivery in women with PE 0.43 Remainder from above IPD
Caesarean section in women with GDM 0.344 Beta(373, 711) IPD
Assisted delivery in women with GDM 0.111 Beta(120, 964) IPD
Normal delivery in women with GDM 0.545 Remainder from above IPD
Caesarean section in women with PIH 0.279 Beta(107, 276) IPD
Assisted delivery in women with PIH 0.154 Beta(59, 324) IPD
Normal delivery in women with PIH 0.567 Remainder from above IPD
Caesarean section in women with no complications 0.355 Beta(660, 1198) IPD
Assisted delivery in women with no complications 0.119 Beta(222, 1636) IPD
Normal delivery in women with no complications 0.525 Remainder from above IPD
Note
Values of α and β are given for beta distributions. The base-case values were used to produce deterministic results.
The distributions were used to undertake probabilistic sensitivity analysis, produce the probabilistic results and produce the
incremental cost-effectiveness scatterplots.
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intervention were thus extracted for five studies68,127–129,132 and the median value was used to estimate the
cost of the intervention in the model (Table 24).
Estimates of antenatal and postnatal care costs were drawn from systematic reviews of the literature
(as described in the previous section on assumptions). Delivery costs were based on national average costs
in the UK.97
Analysis
The decision-analytic model was constructed to compare the cost-effectiveness of diet- and physical
activity-based interventions in pregnancy with usual care. Two separate economic analyses were conducted.
The main analysis compared costs and outcomes for a hypothetical cohort of 10,000 pregnant women,
based on the results of the IPD meta-analysis for all women. The secondary analysis compared costs
and outcomes for three subgroups of women based on their pre-pregnancy BMI classification. Women
were classified as normal weight (pre-pregnancy BMI of < 25 kg/m2), overweight (pre-pregnancy BMI
25–29.9 kg/m2) or obese (pre-pregnancy BMI of ≥ 30 kg/m2). This allowed an exploration of whether or not
a weight management intervention in selective subgroups of women is a more cost-effective strategy than
care as usual.
For both the primary and secondary analyses, the relative cost-effectiveness of the intervention was
evaluated using effect size estimates from the IPD meta-analysis. An incremental approach was adopted,
with a focus on the additional costs and benefits associated with a move from care as usual to diet and
lifestyle interventions to manage weight gain in pregnancy. The results were reported in terms of an
incremental cost-effectiveness ratio (ICER) of cost per unit benefit gained, measured in clinical outcomes.
TABLE 23 Fetal outcomes
Description Base-case value Distribution and values Source
Intrauterine infant death: women with PE 0.03 Beta(1, 358) IPD
Intrauterine infant death: women with GDM 0.02 Beta(2, 888) IPD
Intrauterine infant death: women with PIH 0.03 Beta(1, 332) IPD
Intrauterine infant death: women with no complications 0.03 Beta(4, 1578) IPD
LGA: women with PE 0.096 Beta(38, 356) IPD
LGA: women with GDM 0.156 Beta(171, 928) IPD
LGA: women with PIH 0.109 Beta(42, 344) IPD
LGA: women with no complications 0.134 Beta(251, 1628) IPD
SGA: women with PE 0.193 Beta(76, 318) IPD
SGA: women with GDM 0.091 Beta(98, 984) IPD
SGA: women with PIH 0.123 Beta(47, 336) IPD
SGA: women with no complications 0.119 Beta(221, 1638) IPD
Infant admission to the NICU: women with PE 0.195 Beta(71, 294) IPD
Infant admission to the NICU: women with GDM 0.115 Beta(106, 814) IPD
Infant admission to the NICU: women with PIH 0.057 Beta(19, 312) IPD
Infant admission to the NICU: women with no complications 0.121 Beta(196, 1420) IPD
Note
Values of α and β are given for beta distributions. The base-case values were used to produce deterministic results.
The distributions were used to undertake probabilistic sensitivity analysis, produce the probabilistic results and produce the
incremental cost-effectiveness scatterplots.
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The IPD meta-analysis was based on a composite outcome, which included maternal and fetal
complications. An economic evaluation based on such a composite outcome would not be meaningful,
as the full extent of the cost implications based on such an outcome would be lost. The economic analysis
therefore examined cost-effectiveness for each of the primary outcomes separately; for example, results are
presented in terms of cost per case of PE avoided, cost per case of GDM avoided, etc. Results are also
presented in terms of cost per major outcome avoided. The major outcome was predefined to include one
TABLE 24 Cost data used in the model
Description
Base-case
value (£)
Distribution and
values Source
Intervention to manage weight gain in pregnancy 217 Gamma(1, 413) Calculated valuea
Cost of antenatal care: women with PE 2054 Gamma(1, 2054) van Baaren et al.113
Cost of antenatal care: women with GDM 1022 Gamma(1, 1022) NICE99
Cost of antenatal care: women with PIH 974 Gamma(1, 974) Vijgen et al.117
Cost of preterm delivery, no complications (NZ17B,
CC score of 0–1)
642 Gamma(1, 642) Department of Health97
Cost of preterm delivery, with complications (NZ17A,
CC score of ≥ 2)
946 Gamma(1, 946) Department of Health97
Cost of normal delivery, with no complications (NZ30C,
CC score of 0)
1461 Gamma(1, 1461) Department of Health97
Cost of normal delivery, with minor complications
(NZ30B, CC score of 1)
1623 Gamma(1, 1623) Department of Health97
Cost of normal delivery, with major complications
(NZ30A, CC score of ≥ 2)
1892 Gamma(1, 1892) Department of Health97
Cost of assisted delivery, without complications (NZ40C,
CC score of 0)
1860 Gamma(1, 1860) Department of Health97
Cost of assisted delivery, with minor complications
(NZ40C, CC score of 1 or 2)
2153 Gamma(1, 2153) Department of Health97
Cost of assisted delivery, with major complications
(NZ40A, CC score of 2)
2625 Gamma(1, 2625) Department of Health97
Cost of Caesarean section, without complications
(NZ40C, CC score of 0 or 1)
3363 Gamma(1, 3363) Department of Health97
Cost of Caesarean section, with minor complications
(NZ40C, CC score of 2 or 3)
4059 Gamma(1, 4059) Department of Health97
Intensive care (XC04Z, adult critical care, three organs
supported)
789 Gamma(1, 789) Department of Health97
Cost of neonatal critical care: intensive care 1118 Gamma(1, 1118) Department of Health97
Cost of postnatal care: women with PE 4987 Gamma(1, 4987) van Baaren et al.113
Cost of postnatal care: women with GDM 1899 Gamma(1, 1899) Kolu et al.120
Cost of postnatal care: women with PIH 1814 Gamma(1, 1814) Vijgen et al.117
Additional cost of IUD (core-recommended investigations
and care immediately following miscarriage)
1242 Gamma(1, 1242) Mistry et al.110
CC, complications and comorbidity.
a Median value of intervention costs for studies identified in the systematic review.
Note
Values of α and β are given for gamma distributions. The base-case values were used to produce deterministic results.
The distributions were used to undertake probabilistic sensitivity analysis, produce the probabilistic results and produce the
incremental cost-effectiveness scatterplots.
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or more of the fetal and maternal outcomes included in the composite measure that was used in the IPD
meta-analysis.
The analysis was conducted from the perspective of the health service (NHS) and only direct health service
costs were included. The time horizon adopted for both the primary and secondary analyses was from
the start of pregnancy until the mother and infant were discharged from hospital following the birth.
This was considered appropriate to reflect all key differences in terms of costs and benefits for the options
compared, given the time horizon adopted in the trials included in the IPD meta-analysis. The effect of
considering a longer time horizon was explored as part of the sensitivity analysis.
Sensitivity analysis
Deterministic and probabilistic sensitivity analyses were conducted to explore the effects of the inherent
uncertainty in the parameter estimates on the results produced by the model.98 Deterministic sensitivity
analysis involves varying one or more parameters while keeping the others at their baseline value.
Such analysis can help to identify which model inputs are important in leading to a particular decision
from the model, and can help to identify threshold values. A probabilistic sensitivity analysis (PSA) was also
undertaken to allow uncertainty to be represented more comprehensively. A PSA involves varying all
parameters simultaneously, and multiple sets of parameter values are sampled from defined probability
distributions.134 Monte Carlo simulation was used to sample from these distributions to allow the effect of
parameter uncertainty to be evaluated. This involved 1000 repeated random draws from the distributions
to indicate how variation in the model parameters would affect the results and hence illustrate the
decision uncertainty.135 Beta distributions were used for binomial data, log-normal distributions for ORs and
gamma distributions for costs.98 Ideally, when there are more than two possibilities at a chance node, a
Dirichlet distribution would be applied. But to populate a Dirichlet distribution it is necessary that all
included studies have reported data for all the branches from the appropriate chance node. This could be
done if all data sources reported results for all possible branches. However, in this case, some studies did
not report numbers for all branches in the model. For example, the number of LGA infants born to
mothers with GDM was reported in 27 studies, but the numbers of SGA infants was reported in only
26 studies. Therefore, it is feasible to assign separate beta distributions only for the probabilities of each of
these two outcomes. For consistency, we considered it appropriate to apply beta distributions throughout.
The potential limitation of applying a beta distribution is that some correlation between parameters could
be lost. However, in this study, this is unlikely to have had an impact on results.
Using the net monetary benefit for each of the 1000 simulations, the proportion of times the intervention
had the highest net monetary benefit was calculated for a range of threshold values for the maximum
willingness to pay for a major outcome averted. These values were summarised graphically using a
cost-effectiveness acceptability curve (CEAC) to show the uncertainty surrounding the cost-effectiveness of
the intervention, for a range of thresholds for cost-effectiveness. A value of information analysis was also
conducted to estimate the expected costs of uncertainty. The expected cost of uncertainty is calculated by
estimating the probability of making a wrong decision based on existing evidence and the consequences
of this wrong decision. The expected value of perfect information (EVPI) estimates the difference between
the expected value of the decision made with perfect information and the decision made on the basis of
existing evidence.98 EVPI was calculated based on the methods described in Claxton and Posnett.136
Deterministic sensitivity analysis
A range of deterministic sensitivity analyses was carried out for the primary and secondary analyses.
Both univariate and multivariate analyses were undertaken to assess how uncertainty around the
parameters used in the model would impact on the results achieved. Univariate sensitivity analysis involves
varying input values one at a time across a plausible range while holding the remaining values at their
baseline values, while multivariate analysis involves varying two or more input values simultaneously.136
Six univariate and two multivariate analyses were undertaken based on the following justifications.
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Univariate analyses
1. The cost of the intervention was varied to reflect the maximum and minimum costs identified in the
literature review (£136 and £1023, respectively). The base-case value was estimated based on the
median cost reported in the identified studies and these costs were varied to examine the impact
on results.
2. The effect of the intervention in increasing or reducing the odds of developing pregnancy-related
conditions was varied using 95% CIs for pregnancy-related conditions: PE, 95% CI 0.79 to 1.24; GDM,
95% CI 0.72 to 110; and PIH, 95% CI 0.69 to 1.25.
3. The rate of preterm delivery and Caesarean section varied for each condition separately using 95% CIs
calculated using an exact method.137,138 The rate of preterm delivery varied for women with PE from
19.3% to 27.8%, for those with GDM from 6.1% to 9.3% and for women with PIH from 3% to
7.6%. The rate of Caesarean section varied from 41% to 51.1% for women with PE, from 31.6%
to 37.3% for those with GDM and from 23.5% to 32.7% for those with PIH.
4. The costs associated with health care were increased and decreased for each condition. The costs of
care before and after the birth were varied drawing on the results of the literature review. The total
costs of care for women with PE varied from £4476104 to £12,052 (this was based on the highest
estimate of the costs of PE identified, with a 15% increase102). The costs of delivery and postnatal care
for women with PIH varied from £2988104 to £5530 (the higher cost included follow-up care117). The
total costs associated with care for women with GDM varied between £3105130 (estimate for women
with mild GDM) and £8753.131
5. The costs of delivery were varied using the upper- and lower-quartile costs reported for elective and
non-elective deliveries reported in the National Schedule of Reference Costs: The Main Schedule.97
Thus, the costs of Caesarean section with a complications and comorbidities score of 0 or 1 varied from
£1818 (planned elective delivery, lower-quartile cost) to £4289 (emergency delivery, non-elective
patient, upper-quartile cost). The cost of a Caesarean section with a complications and comorbidities
score of ≥ 2 varied from £2085 (planned elective delivery, lower-quartile cost) to £4289 (emergency
delivery, non-elective patient, upper-quartile cost). For assisted deliveries, the costs of delivery varied
for deliveries with no complications (£960–2721, reflecting non-elective short-stay lower-quartile
costs and long-stay upper-quartile costs, respectively), a complications score of 1 (£1033–3050, for
non-elective short-stay and long-stay costs, respectively) and a complications and comorbidities score of
2 (£1132–3604, non-elective short-stay and long-stay costs, respectively). For normal deliveries, similar
variations in costs were explored; costs were varied for deliveries with no complications (£854–2688,
reflecting non-elective short-stay lower-quartile costs and long-stay upper-quartile costs, respectively),
deliveries with a complications and comorbidities score of 1 (£898–2968, for non-elective short-stay and
long-stay costs, respectively) and develieries with a complication score of 2 (£957–3349, non-elective
short-stay and long-stay costs, respectively).
6. Increasing the costs of IUD. The costs associated with IUD were increased using estimates provided in a
published review of the literature.110 The costs of IUD were increased to £1804 to reflect the increased
costs associated with comprehensive investigations.
Multivariate analyses
Multivariate analyses were undertaken to reflect the fact that a change in the clinical effectiveness of the
intervention is likely to affect more than one outcome measure. Hence, multiple parameters were varied
simultaneously to examine the impact on the results:
1. Varying the effectiveness for all pregnancy-related conditions. For this analysis, CIs were used to
examine the impact on cost-effectiveness using the highest and lowest estimates of effect.
2. Increasing and decreasing the cost of pregnancy-related conditions. All costs associated with
pregnancy-related conditions were increased and decreased simultaneously using the estimates from
the literature.
DOI: 10.3310/hta21410 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 41
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Rogozin´ska et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
Results
Primary analysis
The results of the primary analysis are reported in Tables 25 and 26. Care as usual was the least costly
arm, with the average cost estimated at £3242 (excluding routine antenatal care). However, the
intervention arm was only slightly more expensive, with average costs estimated at £3390 (excluding
routine antenatal care). In the base-case model (using point estimates) there was a reduction in
pregnancy-related complications in the intervention arm (see Table 26). Overall, there were 55 fewer
women who experienced any major outcome in the intervention arm, five fewer cases of PE, 113 fewer
cases of GDM and 29 fewer women who developed PIH. No reduction was found in other outcomes such
as preterm delivery, Caesarean section, IUD, LGA and NICU admission for the intervention arm. The ICERs
indicated that there was an additional cost of around £306,000 for each case of PE avoided, £13,000 for
each case of GDM avoided and £27,000 for each woman with a major outcome avoided. This means that,
if for example, the outcome of interest is the reduction in cases of PE, an additional £306,000 is required
for each additional woman who avoids the development of PE compared with usual care. These results
taken in isolation would suggest that the intervention would be preferred at any willingness to pay for a
case of PE avoided above £306,000.
TABLE 26 Results for primary base-case analysis for a cohort of 10,000 women
Outcome
Number of women experiencing
complications Number of complications
avoided per 10,000 women:
outcome averted
(point estimate)
Cost (£) per
complication
avoideda
Intervention
(point estimate)
No intervention
(point estimate)
Any major outcome 6981 7036 55 27,000
PE 495 499 5 306,000
GDM 1029 1142 113 13,000
PIH 398 426 29 51,000
Preterm delivery 1037 1033 –4 b
Caesarean section 3526 3523 –3 b
IUD 25 25 0 b
LGA 1608 1605 –4 b
SGA 888 891 3
NICU admission 1202 1200 –2 b
a Cost per complication avoided is rounded to the nearest £1000.
b Intervention less clinically effective than care as usual.
TABLE 25 Average costs (£) for intervention group compared with care as usual
Group allocation Total cost (point estimate)a Difference in costs
Intervention 3390 147
No intervention 3242
a As it was assumed that routine antenatal care was received by all women this was not included in the total costs as
there would be no difference in costs between model arms.
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These results need to be viewed together with those from the PSA (Tables 27 and 28). The PSA results
show the modelled uncertainty in the cost and effectiveness between the intervention arm and the
care-as-usual arm, from 1000 Monte Carlo simulations. These results show that it is uncertain whether the
intervention is more effective than usual care or less effective (with respect to all the outcome measures)
and whether the intervention is more costly or less expensive than the alternative. Hence, the most
reasonable interpretation is that there is no significant difference between the intervention and control arm
results for either cost or clinical effectiveness. This is further illustrated by Figure 12. The graph plots the
result of each simulation on the cost-effectiveness plane, which gives information about the joint density
of differences in cost and effectiveness between the two model arms. It is evident that the data in the
scatterplot go into all quadrants of the incremental cost-effectiveness plane and, therefore, it should be
assumed that there is no significant difference between the intervention and control arms for either cost or
clinical effectiveness. This was the case for all of the outcome measures (for more details see Appendix 11).
The CEAC (Figure 13) shows that the probability that the intervention is cost-effective increases as the
willingness to pay for a major outcome averted increases. Thus, if the maximum willingness to pay for a
major outcome averted for all pregnant women was £30,000, then the probability that the intervention
was cost-effective would be 0.55.
TABLE 27 Results of PSA: average costs (£) for intervention group compared with care as usuala
Group allocation
Cost (95% CI)
Mean Difference
Intervention 3457 (1651 to 6408) 151 (–247 to 754)
No interventionb 3306 (1432 to 6088)
a Note that the mean results in the PSA are not the same as the point estimates used in the base-case analysis because of
the use of log-normal distributions which create a non-linearity in the model.
b As it was assumed that routine antenatal care was received by all women this was not included in the total costs as
there would be no difference in these costs between model arms.
TABLE 28 Results of PSA: primary analysis for a cohort of 10,000 womena
Outcome
Number of women experiencing complications,
mean (95% CI)
Number of complications avoided
per 10,000 women (95% CI)Intervention No intervention
Any major outcome 6984 (6758 to 7202) 7036 (6875 to 7209) 52 (–88 to 172)
PE 496 (381 to 635) 498 (432 to 567) 3 (–116 to 103)
GDM 1032 (825 to 1278) 1142 (1050 to 1230) 109 (–117 to 307)
PIH 401 (289 to 547) 426 (369 to 491) 25 (–100 to 134)
Preterm delivery 1036 (921 to 1153) 1032 (923 to 1150) –4 (–15 to 7)
Caesarean section 3529 (3329 to 3718) 3527 (3336 to 3714) –3 (–17 to 13)
IUD 25 (9 to 52) 25 (9 to 51) 0 (–1 to 1)
LGA 1608 (1474 to 1742) 1605 (1471 to 1739) –3 (–18 to 12)
SGA 889 (800 to 975) 891 (808 to 975) 2 (–14 to 18)
NICU admission 1201 (1073 to 1333) 1199 (1074 to 1328) –2 (–13 to 10)
a Note that the mean results in the PSA are not the same as the point estimates used in the base-case analysis because of
the use of log-normal distributions which create a non-linearity in the model.
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The analysis of the EVPI demonstrates that at a willingness-to-pay threshold of £30,000 to avert a major
outcome, the expected value of resolving the uncertainty around the decision is £142 per patient to whom
the decision would apply (Figure 14). Thus, for a cohort of 10,000 women, the EVPI would be £1,420,000.
Secondary analysis
Obese women
The results of the secondary analysis for obese women are reported in Tables 29 and 30. Care as usual
was the least costly arm for obese women, with an average cost estimated at £3428 (excluding routine
antenatal care). However, the intervention arm was only slightly more expensive, with average costs
estimated at £3613 (excluding routine antenatal care). In the base-case model (using point estimates)
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FIGURE 12 Incremental cost-effectiveness scatterplot of intervention compared with care as usual for pregnant
women: major outcome averted. The mean of the distribution is highlighted.
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FIGURE 13 Incremental CEAC of intervention for pregnant women: major outcome averted.
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TABLE 29 Average costs (£) for intervention group compared with care as usual: obese women
Group allocation
Cost
Mean (point estimate) Difference
Intervention 3613 185
No interventiona 3428
a As it was assumed that routine antenatal care was received by all women this was not included in the total costs,
as there would be no difference in these costs between model arms.
TABLE 30 Results for analysis for a cohort of 10,000 obese women
Outcome
Number of women experiencing
complications (point estimate)
Number of complications
avoided per 10,000 women:
outcome averted
(point estimate)
Cost (£) per
complication
avoidedaIntervention No intervention
Any major outcome 7248 7269 21 88,000
PE 550 530 –20 b
GDM 1512 1637 125 15,000
PIH 562 514 –48 b
Preterm delivery 1021 1018 –3 b
Caesarean section 3514 3514 0 b
IUD 25 25 0 b
LGA 1587 1589 3 712,000
SGA 905 902 –3 b
NICU admission 1192 1193 1 2,057,000
a Cost per complication avoided is rounded to the nearest £1000.
b Intervention is less clinically effective than care as usual/no difference in clinical effectiveness.
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there were 21 fewer obese women who experienced any major outcome in the intervention arm and 125
fewer cases of GDM. No reduction was found in other outcomes such as the development of PE, PIH and
rates of preterm delivery, Caesarean section, IUD, LGA and NICU admission. The ICERs indicated that there
was an additional cost of around £88,000 for each major outcome avoided and £15,000 for each case
of GDM avoided. The PSA results show the modelled uncertainty in the cost and clinical effectiveness
between the intervention arm and the care-as-usual arm and demonstrate that it is uncertain whether the
intervention is more or less effective than usual care and whether the intervention is more or less costly than
the alternative (Tables 31 and 32). These results suggest that there is no significant difference between the
intervention and the control arm results for either cost or clinical effectiveness for obese women. This is
further illustrated by Figure 15, which plots the result of each simulation on the cost-effectiveness plane and
shows that there is no significant difference between the intervention and control arms for either cost or
clinical effectiveness for all outcome measures (for more details see Appendix 11). The CEAC (Figure 16)
shows if the maximum willingness to pay for a major outcome averted for obese pregnant women was
£120,000, then the probability that the intervention was cost-effective would be 0.52.
TABLE 31 Results of PSA: average costs (£) for intervention group compared with care as usual for obese womena
Group allocation
Cost (95% CI)
Mean Difference
Intervention 3675 (1794 to 6321) 191 (–247 to 809)
No interventionb 3484 (1608 to 6129)
a Note that the mean results in the PSA are not the same as the point estimates used in the base-case analysis because of
the use of log-normal distributions which create a non-linearity in the model.
b As it was assumed that routine antenatal care was received by all women this was not included in the total costs, as
there would be no difference in these costs between model arms.
TABLE 32 Results of PSA: analysis for a cohort of 10,000 obese womena
Outcome
Number of women experiencing complications,
mean (95% CI)
Number of complications avoided
per 10,000 women (95% CI)Intervention No intervention
Any major outcome 7252 (6992 to 7524) 7268 (7108 to 7444) 16 (–194 to 197)
PE 553 (396 to 750) 529 (437 to 630) –24 (–189 to 108)
GDM 1517 (1164 to 1940) 1636 (1482 to 1786) 119 (–262 to 445)
PIH 564 (403 to 778) 513 (420 to 615) –51 (–223 to 95)
Preterm delivery 1021 (912 to 1130) 1018 (911 to 1125) –3 (–17 to 10)
Caesarean section 3518 (3329 to 3700) 3518 (3336 to 3699) 1 (–19 to 21)
IUD 25 (10 to 50) 25 (10 to 49) 0 (–1 to 1)
LGA 1587 (1463 to 1716) 1590 (1463 to 1720) 3 (–17 to 25)
SGA 906 (820 to 993) 903 (822 to 985) –4 (–27 to 16)
NICU admission 1192 (1070 to 1316) 1193 (1076 to 1319) 1 (–15 to 16)
a Note that the mean results in the PSA are not the same as the point estimates used in the base-case analysis because of
the use of log-normal distributions which create a non-linearity in the model.
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Overweight women
The results of the secondary analysis for overweight women are reported in Tables 33 and 34. As for
obese women, care as usual had the lowest cost, with the average cost estimated at £3114 (excluding
routine antenatal care). The intervention arm was slightly more expensive, with average costs estimated at
£3326 (excluding routine antenatal care). In the base-case model (using point estimates) there were
115 fewer overweight women who developed PIH (see Table 34). However, for all other clinical outcomes,
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FIGURE 15 Incremental cost-effectiveness scatterplot of intervention compared with care as usual for obese
pregnant women: major outcome averted. The mean of the distribution is highlighted.
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FIGURE 16 Incremental CEAC of intervention for obese pregnant women: major outcome averted.
TABLE 33 Average costs (£) for intervention group compared with care as usual: overweight women
Group allocation
Cost
Total (point estimate) Difference
Intervention 3326 211
No interventiona 3114
a As it was assumed that routine antenatal care was received by all women this was not included in the total costs,
as there would be no difference in these costs between model arms.
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the intervention did not lead to a reduction in adverse outcomes. The PSA results allow an assessment
of the uncertainty in the estimates of cost and clinical effectiveness between the intervention arm and the
care-as-usual arm (Tables 35 and 36). It is evident that it is uncertain whether the intervention is more
or less effective than usual care and whether the costs associated with the intervention arm are greater or
lower than the alternative. Hence, there is no significant difference between the intervention and control
arm results for either cost or effectiveness for overweight women. This is further illustrated by Figure 17,
which plots the result of each simulation on the cost-effectiveness plane and shows that no significant
differences were found between the intervention arm and control arm for either cost or effectiveness
(for more details see Appendix 11). The CEAC (Figure 18) shows that, even if the maximum willingness to
pay for a major outcome averted for overweight pregnant women was £500,000, then the probability that
the intervention is cost-effective would be < 0.5.
Normal weight women
The results of the secondary analysis for normal weight women are reported in Tables 37 and 38.
The intervention arm had the lowest costs, with an average cost estimated at £3056 (excluding routine
antenatal care). This was because the additional costs associated with delivering the intervention were
outweighed by savings associated with reduced health-care use overall. However, the care-as-usual arm
was only slightly more expensive, with average costs estimated at £3063 (excluding routine antenatal care).
TABLE 34 Results for analysis for a cohort of 10,000 overweight women
Outcome
Number of women experiencing
complications (point estimate) Number of complications
avoided per 10,000 women
(point estimate)
Cost (£) per
complication
avoidedIntervention No intervention
Any major outcome 6915 6903 –11 a
PE 459 439 –21 a
GDM 996 871 –126 a
PIH 293 407 115 18,000
Preterm delivery 1039 1034 –5 a
Caesarean section 3531 3521 –10 a
IUD 25 25 0 a
LGA 1618 1614 –4 a
SGA 879 881 1 1,621,000
NICU admission 1206 1198 –8 a
a Intervention is less clinically effective than care as usual/no difference in clinical effectiveness.
TABLE 35 Results of PSA: average costs (£) for intervention group compared with care as usual for overweight
womena
Group allocation
Cost (95% CI)
Mean Difference
Intervention 3399 (1546 to 6419) 231 (–279 to 980)
No interventionb 3169 (1334 to 6002)
a Note that the mean results in the PSA are not the same as the point estimates used in the base-case analysis because of
the use of log-normal distributions which create a non-linearity in the model.
b As it was assumed that routine antenatal care was received by all women this was not included in the total costs,
as there would be no difference in these costs between model arms.
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In the base-case model (using point estimates) there were 108 fewer women who experienced any major
outcome in the intervention arm, 231 fewer cases of PE and 53 fewer women who developed GDM. There
were also reductions in the rate of preterm delivery, Caesarean section, IUD, SGA, and NICU admission.
The results suggested that, for most clinical outcome measures reported, the intervention was less costly
and more effective than care as usual. These results need to be considered alongside the results of
the PSA (Tables 39 and 40). The PSA results show the modelled uncertainty in terms of the cost and the
effectiveness for the intervention arm and the care-as-usual arms. The findings suggest that it is uncertain
whether the intervention is more or less effective than usual care and whether the intervention costs
are higher or lower than the costs associated with usual care. Hence, there is no significant difference
between the intervention and the control arm results for either cost or effectiveness for women of
normal weight. This is further illustrated by Figure 19, which plots the result of each simulation on the
TABLE 36 Results of PSA: analysis for a cohort of 10,000 overweight womena
Outcome
Number of women experiencing complications,
mean (95% CI) Number of complications
avoided per 10,000 women
(95% CI)Intervention No intervention
Any major outcome 6930 (6613 to 7318) 6902 (6720 to 7095) –28 (–351 to 206)
PE 472 (248 to 800) 438 (324 to 569) –34 (–325 to 158)
GDM 1019 (581 to 1624) 871 (712 to 1031) –148 (–703 to 257)
PIH 299 (159 to 530) 405 (299 to 530) 107 (–72 to 265)
Preterm delivery 1039 (921 to 1159) 1033 (915 to 1150) –6 (–31 to 12)
Caesarean section 3535 (3328 to 3729) 3525 (3328 to 3714) –10 (–43 to 14)
IUD 25 (9 to 52) 26 (9 to 53) 0 (–2 to 2)
LGA 1616 (1482 to 1759) 1614 (1475 to 1754) –2 (–25 to 32)
SGA 882 (785 to 974) 882 (796 to 970) 0 (–40 to 27)
NICU admission 1206 (1073 to 1341) 1197 (1068 to 1332) –9 (–33 to 9)
a Note that the mean results in the PSA are not the same as the point estimates used in the base-case analysis because of
the use of log-normal distributions which create a non-linearity in the model.
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FIGURE 17 Incremental cost-effectiveness scatterplot of intervention compared with care as usual for overweight
pregnant women: major outcome averted. The mean of the distribution is highlighted.
DOI: 10.3310/hta21410 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 41
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Rogozin´ska et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
TABLE 37 Average costs (£) for intervention group compared with care as usual: women of normal weight
Group allocation
Cost
Mean (point estimate) Difference
Intervention 3056 –7
No interventiona 3063
a As it was assumed that routine antenatal care was received by all women this was not included in the total costs,
as there would be no difference in these costs between intervention arms.
TABLE 38 Results of analysis for a cohort of 10,000 normal weight women
Outcome
Number of women experiencing
complications (point estimate) Number of complications
avoided per 10,000 women
(point estimate)
Cost (£) per
complication
avoidedIntervention No interventiona
Any major outcome 6677 6785 108 b
PE 275 506 231 b
GDM 573 626 53 b
PIH 274 274 0 b
Preterm delivery 1029 1056 28 b
Caesarean section 3518 3541 24 b
IUD 25 25 0 b
LGA 1639 1621 –18 c
SGA 854 880 26 b
NICU admission 1197 1213 17 b
a As it was assumed that routine antenatal care was received by all women this was not included in the total costs,
as there would be no difference in costs between intervention arms.
b Intervention dominates usual care.
c Intervention is less clinically effective than care as usual/no clinical difference in effectiveness.
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FIGURE 18 Incremental CEAC of intervention for overweight pregnant women: major outcome averted.
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TABLE 39 Results of PSA: average costs (£) for intervention group compared with care as usual for normal
weight womena
Outcome
Cost (95% CI)
Mean Difference
Intervention 3140 (1244 to 6264) 22 (–563 to 741)
No interventionb 3118 (1265 to 6041)
a Note that the mean results in the PSA are not the same as the point estimates used in the base-case analysis because of
the use of log-normal distributions which create a non-linearity in the model.
b As it was assumed that routine antenatal care was received by all women this was not included in the total costs,
as there would be no difference in costs between intervention arms.
TABLE 40 Results of PSA: analysis for a cohort of 10,000 normal weight womena
Outcome
Number of women experiencing complications,
mean (95% CI) Number of complications
avoided per 10,000 women
(95% CI)Intervention No intervention
Any major outcome 6704 (6403 to 7068) 6784 (6599 to 6972) 80 (–240 to 286)
PE 290 (121 to 580) 505 (376 to 662) 214 (–44 to 394)
GDM 603 (275 to 1125) 627 (504 to 757) 24 (–466 to 340)
PIH 299 (96 to 725) 272 (186 to 379) –27 (–421 to 195)
Preterm delivery 1028 (908 to 1155) 1056 (933 to 1179) 28 (4 to 59)
Caesarean section 3520 (3302 to 3722) 3545 (3345 to 3736) 24 (–5 to 62)
IUD 26 (8 to 54) 26 (9 to 53) 0 (–2 to 2)
LGA 1636 (1493 to 1780) 1621 (1481 to 1760) –15 (–43 to 24)
SGA 858 (761 to 954) 882 (793 to 972) 23 (–13 to 54)
NICU admission 1195 (1055 to 1337) 1212 (1080 to 1352) 17 (–6 to 50)
a Note that the mean results in the PSA are not the same as the point estimates used in the base-case analysis because of
the use of log-normal distributions which create a non-linearity in the model.
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FIGURE 19 Incremental cost-effectiveness scatterplot of intervention compared with care as usual for normal
weight pregnant women: major outcome averted. The mean of the distribution is highlighted.
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cost-effectiveness plane and shows that, although there is a trend towards lower cost and increased
effectiveness for the intervention arm, there is no statistically significant difference between the intervention
and the control arms for either cost or effectiveness (see more details in Appendix 11). The CEAC (Figure 20)
shows that as the willingness to pay for a major outcome averted for normal weight women increases, the
probability that the intervention is cost-effective also increases. Thus, if the threshold for cost-effectiveness
was £30,000 to avert a major outcome for normal weight women, then the probability that the intervention
was cost-effective would be 0.67.
Deterministic sensitivity analysis
As demonstrated in Table 41, the results of the deterministic sensitivity analysis were as follows: (1) varying
the cost of the intervention affected the average cost of the intervention arm and the cost per major
outcome avoided, with this rising to £170,000 per major outcome avoided for the highest intervention
cost; (2) improving the effect of the intervention meant that the intervention arm was more cost-effective
than the control arm, the model was particularly sensitive to the estimate of the effect of the intervention
on the odds of developing of PE; (3) varying the timing and mode of delivery did not change the overall
result for the development of pregnancy-related conditions; (4) increasing and decreasing the costs for
each condition had some impact on the overall results; (5) varying the costs associated with various types
of delivery had a negligible effect on the overall results; and (6) increasing the costs of IUD had a negligible
impact on overall results. As expected, the multivariate analyses demonstrated that using the highest
estimates of effectiveness meant that the intervention arm dominated the control arm (it was less costly
and more effective), as the additional costs of the intervention were outweighed by lower health-care
resource use.
Discussion
Principal findings
The results of this analysis suggest that there is no evidence that mixed interventions in pregnancy are
cost-effective compared with care as usual. Although the primary base-case analysis indicated a small
reduction in pregnancy-related complications, the PSA demonstrated that there is no evidence of a
significant difference between the intervention and the control arms for either cost or clinical effectiveness.
Similarly, the results of the secondary analysis suggested that for obese, overweight and normal weight
women it is uncertain whether or not the intervention is more clinically effective than usual care (with
respect to all the outcome measures) and whether or not the intervention is more costly than the
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TABLE 41 Deterministic sensitivity analysis: selected results
Scenarios
Value Result
Original Revised Original Revised
Univariate analyses
(1) Varying the costs
of the intervention
£217 £136–1023 Cost of intervention
arm: £3390
Cost of intervention
arm: £3309–4187
Cost per major outcome
avoided: £26,000
Cost per major
outcome avoided:
£12,000–170,000
(2) Changing the
intervention effect
[development of
pregnancy-related
conditions (OR)]
PE: 0.99 PE: 0.79–1.24 Cases of PE avoided: 5 Cases of PE avoided:
101 to –112
GDM: 0.89 GDM: 0.72–1.10 Cost per case of PE
avoided: £306,000
Cost per case of PE
avoided: £7000a
PIH: 0.93 PIH: 0.37–2.73 Cases of GDM avoided:
113
Cases of GDM
avoided: 293 to –100
Cost per case of GDM
avoided: £13,000
Cost per case of GDM
avoided: £3000a
Cases of PIH avoided: 29 Cases of PIH avoided:
128 to –101
Cost per case of PIH
avoided: £51,000
Cost per case of PIH
avoided: £9000a
(3) Varying the
timing and mode of
delivery
Preterm delivery:
l PE: 0.234
l GDM: 0.076
l PIH: 0.049
Preterm delivery:
l PE: 0.193–0.278
l GDM: 0.061–0.093
l PIH: 0.03–0.076
Cost per case of PE
avoided: £306,000
Unchanged
Cost per case of GDM
avoided: £13,000
Caesarean section:
l PE: 0.46
l GDM: 0.279
l PIH: 0.355
Caesarean section:
l PE: 0.410–0.511
l GDM: 0.316–0.373
l PIH: 0.235–0.327
Cost per case of PIH
avoided £51,000
(4) Increasing and
decreasing the costs
for each condition
Varies according to
pathway
PE: £4476–12,052 Cost per case of PE
avoided: £306,000
Cost per case of PE
avoided: £312,000–
305,000
GDM: £3105–8753 Cost per case of GDM
avoided: £13,000
Cost per case of GDM
avoided: £15,000–
10,000
PIH: £2988–5530 Cost per case of PIH
avoided £51,000
Cost per case of PIH
avoided £53,000–
51,000
(5) Varying the costs
associated with
various types of
delivery
Caesarean section
(CC score of 0 or 1):
£3363
Caesarean section
(CC score of 0–1):
£1818–4289
Cost per major outcome
avoided: £27,000
Cost per major
outcome avoided:
£26,000–27,000
Caesarean section
(CC score of 2 or 3):
£4059
Caesarean section
(CC score of 2–3):
£2085–4289
Normal delivery
(CC score of 0): 1461
Normal delivery
(CC score of 0):
854–2688
Normal delivery
(CC score of 1): 1623
Normal delivery
(CC score of 1):
898–2968
continued
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alternative. The results of the deterministic sensitivity analyses demonstrated that the results were
particularly sensitive to the estimates of the treatment effect in terms of the odds of developing PE.
Strengths and limitations of the economic study
The strength of this model-based economic evaluation is that the effect of interventions to manage weight
gain in pregnancy was estimated via an IPD meta-analysis, involving data relating to 17,727 women and
30 studies. Furthermore, the resource use data were collected via a series of systematic reviews to identify
studies that collected primary cost data. These reviews involved wide and detailed search and inclusion
strategies. In addition, the study benefited from significant clinical input throughout its design and
development. This study contributes to an area in which there is a paucity of economic studies.101
The current public health emphasis on obesity and healthy lifestyles139 highlights the importance of
contributions to understanding the costs and benefits of interventions in this area.
There were also some weaknesses. First, limited evidence was available about the resource use associated
with some conditions in pregnancy. Although resource use data from high-quality RCTs were used to inform
the model, the paucity of studies available limited the comparisons that could be undertaken to examine
variations in costs for different groups of patients. A second limitation was that the study included a wide
range of studies with different kinds of intervention models. This meant that it was difficult to estimate the
costs associated with the intervention precisely; instead a median value was used, based on the findings of a
systematic review. The cost of the intervention varied widely in the sensitivity analysis to account for the
diversity of intervention types included in the IPD meta-analysis. In addition, for some outcomes, such as
admission to the NICU of an infant whose mother did not have a pregnancy-related complication, it was
difficult to obtain robust estimates of resource use. To address this limitation, the sensitivity analysis explored a
TABLE 41 Deterministic sensitivity analysis: selected results (continued )
Scenarios
Value Result
Original Revised Original Revised
Normal delivery
(CC score of 2): 1892
Normal delivery
(CC score of 2):
957–3349
(6) Increasing the
costs of IUD
IUD cost: £1242 IUD cost: £1804 Cost per major outcome
avoided: £27,000
Unchanged
Multivariate analyses
(1) Varying
estimates of effect
simultaneously
PE: 0.99 PE: 0.79–1.24 Cost per case of PE
avoided: £306,000
Intervention is cost
saving with highest
estimates of effect and
dominated using
lowest estimates of
effect
GDM: 0.89 GDM: 0.72–1.10 Cost per case of GDM
avoided: £13,000
PIH: 0.93 PIH: 0.37–2.73 Cost per case of PIH
avoided: £51,000
(2) Varying
estimates of cost
simultaneously
Varies according to
pathway
PE: £4476–12,052 Cost per case of PE
avoided: £306,000
Cost per case of PE
avoided: £219,000–
374,000
GDM: £3105–8753 Cost per case of GDM
avoided: £13,000
Cost per case of GDM
avoided: £9000–
16,000
PIH: £2988–5530 Cost per case of PIH
avoided: £51,000
Cost per case of PIH
avoided: £37,000–
63,000
CC, complications and comorbidity.
a Intervention less effective than care as usual.
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wide range of plausible values for the costs associated with pregnancy-related conditions. A further limitation
of the study is that outcomes were expressed in terms of clinical effectiveness rather than in terms that would
allow comparison across programme areas, such as quality-adjusted life-years (QALYs). The absence of robust
QALY data for women who are experiencing pregnancy-related conditions101,136 meant that a full cost–utility
analysis incorporating QALYs was not possible. This means that some of the results are difficult to interpret as
no willingness-to-pay threshold exists for individual clinical outcomes. As the results of the sensitivity analysis
demonstrated that there was no significant difference between the intervention and the control arms results
for either costs or clinical effectiveness, longer-term economic modelling was not undertaken. Finally, the
economic evaluation was based on the results of the IPD meta-analysis. The findings may have been different
if the evaluation had been based on the results of the meta-analysis using aggregated data (as these showed
a statistically significant reduction for some outcomes). Further work could be undertaken to explore
the cost-effectiveness of diet- and physical activity-based interventions using data from the aggregate
meta-analyses, as this was beyond the scope of the current project.
Comparison with other studies
A limited number of studies were identified that were concerned with the costs and benefits of
interventions to promote weight management during pregnancy. Only one study was identified that
concluded that such an intervention was cost-effective. Dodd et al.128 concluded that an intervention
involving a lifestyle advice service was likely to be cost-effective using a monetary value of AUD 20,000 as
a threshold for avoiding additional infants with a birthweight above 4 kg. However, several other studies
have found no evidence of statistically significant differences in outcome measures and concluded that the
intervention to manage weight gain in pregnancy was not cost-effective. For example, Oostdam et al.132
examined the cost-effectiveness of an exercise intervention and concluded that the intervention was
not cost-effective based on a range of outcome measures including infant birthweight and QALYs.
Similarly, Kolu et al. found that a mixed intervention to prevent GDM was not cost-effective based on
improvements in birthweight or 15D instrument scores.129 A large-scale study concluded that a health
training intervention was not cost-effective compared with usual care, based on comparison of QALY gains
and costs for women.68 Finally, a cost-comparison study for a weight-gain restriction programme for obese
women found that that the weight-gain restriction programme was effective but had higher costs.127
Meaning of the study
The results of the economic evaluation suggest that there is no evidence of cost-effectiveness for mixed
interventions to manage weight gain in pregnancy. However, the lack of robust data on the quality of life
of women and infants in the perinatal period means that further research is needed to fully understand
the benefits of such programmes.
Unanswered questions and future research
The results of this economic evaluation highlight the need for accurate data on the quality of life of
mothers and infants in the perinatal period, particularly around the impacts on quality of life for women
with pregnancy-related conditions. This would enable a fuller analysis of the impact of interventions to
manage weight gain in pregnancy on women’s health and that of their children. There is also a need for
further work exploring the longer-term costs of weight gain in pregnancy for the mother and infant.
This would need to include consideration of the wider societal costs of weight gain during pregnancy,
as these are likely to be broader than health alone.
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Chapter 9 Discussion
Summary of findings
Diet- and lifestyle-based interventions have a similar effect in all pregnant women for GWG, composite
maternal and fetal/neonatal outcomes, irrespective of the woman’s characteristics such as BMI at booking,
age, parity, Caucasian ethnicity and underlying medical condition(s). The interventions are effective in
achieving a modest reduction in GWG, but there are no effects on composite maternal and fetal
outcomes. There is no evidence of additional harm to the fetus. Adherence to the IOM-recommended
GWG targets does not significantly reduce the risk of composite maternal or fetal/neonatal outcomes.
Strengths and limitations
Our IPD meta-analysis is the largest to date, and has greater power to detect any differential treatment
effect across groups than single trials or aggregate meta-analysis. We modelled individual risk status
(prognostic factor values) across participants within trials, to assess for variability in patient outcome. This is
in contrast to aggregate data meta-analysis, which can model only average risk status values across studies,
and thus only explain between-study variation. Our findings are more homogeneous, and are less likely to
be affected by selective and biased reporting observed in aggregate meta-analysis. We have included more
participants, and more outcomes than those that are currently available in the published literature by
including available but unpublished data, particularly for outcomes such as preterm birth and SGA fetuses.
Although individual trials identified in our systematic review were powered to detect an overall treatment
effect, the individual trial sample sizes were not sufficient to evaluate an effect in relevant subgroups of
women. The sample size needed to be increased fourfold to have sufficient power to detect an interaction
with the same magnitude as the overall treatment effect, and a 20-fold increase for an interaction term
that is half the size of the overall treatment effect.140 The costs and time to undertake a new trial for this
purpose would be immense. By obtaining IPD from the multiple trials that have already been conducted,
we have increased the sample size beyond a single trial, with substantially increased power to detect
genuine interactions.
We focused on assessing the effect of the intervention on women across the BMI spectrum, including
traditional categories of normal weight, overweight and obese. Ours is the first work to assess the effects
of prognostic factors such as parity, ethnicity and underlying medical condition on the effectiveness of the
intervention. The information about the components of the intervention was obtained in detail, including
the adherence to the intervention by directly contacting the primary researchers. As experiencing more
than one outcome out of GDM, preterm birth and PE was considered to be equally important for clinical
management, we used composite outcome measures. We identified the components of the composite
through a robust and transparent Delphi process.19 The effects of the intervention on the individual
components of the composite showed very similar effect sizes, confirming the valid use of the composite.
We assessed the risk of bias in studies that contributed IPD and compared this with the risk of bias overall
in all published studies. The relationship between GWG and pregnancy outcomes was evaluated using
good-quality randomised data.
We were not able to explore the effects of ethnicity in detailed subcategories because of the wide
variation in the definitions of race and ethnicity in individual studies. Furthermore, our assessment of
differential effects for various individual characteristics was limited to those studies that only included
women from all the subgroups. The trials varied in the type of intervention, duration, intensity, setting,
provider and compliance. We were unable to fully disentangle the components of the intervention, and
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thus to identify those features that are effective in improving outcomes. The variation in criteria for the
diagnosis or definition of GDM and PE may also have influenced the results. All studies that contributed to
IPD were included in the analysis of the composite outcome, as the individual components of the outcome
were not reported in all studies.
Very few studies that evaluated diet provided IPD, affecting the precision of the estimates for diet-based
intervention. We approached all relevant authors within the time frame of the IPD meta-analysis. Although
we identified more studies in the updated search, it was too late within the project to obtain data from
these groups. However, the proportion of individual data not shared was lower than the proportion of
studies not included in the IPD. Availability of additional non-IPD studies to our work may have improved
the precision in our estimates. For validation of weight change as an outcome, we used the data only from
control women, which reduced the available sample size for analysis. Inclusion of both intervention and
control groups may help to improve the precision of the estimates, although precision may also be
affected by the effects of intervention.
Comparison to existing evidence
Current national and international recommendations provide advice on diet and physical activity to
manage weight in pregnancy.10,141,142 These do not quantify the expected benefit to the woman or her
infant from lifestyle-based interventions. They vary in their advice on compliance with weight-gain targets
in pregnancy. Our findings are consistent with the previous systematic review that found a reduction in
GWG.24 Based on the findings of IPD meta-analysis, we were able to provide robust estimates for
composite and individual maternal and fetal/neonatal outcomes, with minimal heterogeneity that limited
previously published reviews.
Our findings on the effect of interventions for fetal/neonatal outcomes are similar to those of the recently
published large studies that found no significant benefit.68,72 Meta-analysis of published aggregate data
showed significant benefit for GDM, preterm birth and Caesarean section compared with the observed
trend in reduction of maternal composite and individual outcomes in our IPD meta-analysis. This is
probably because of the inclusion of additional participants, although there were no large differences in
sample sizes for individual maternal outcomes in both meta-analyses. However, unlike IPD, aggregate
meta-analysis did not account for baseline prognostic factors in assessing the effects of intervention.
In the USA, the IOM guidance recommends weight-gain ranges in pregnancy for normal weight, overweight
and obese women based on observational data.143 In the absence of validation of these data in large
interventional trials, the benefits of adhering to these targets in pregnancy are unclear. We have not found an
association between GWG, including adherence to IOM targets and improvement in pregnancy outcomes.
Relevance to clinical practice
Currently, only obese pregnant women are offered diet and lifestyle interventions, which are often delivered
by dietitians in many hospitals in the UK. Our work has shown that the effects of the interventions do not
vary according to the maternal BMI for reduction in GWG. Existing strategy needs to be broadened to
include normal weight and overweight women, as reduced GWG has the potential to minimise postpartum
weight retention,144 thereby preventing these women from entering subsequent pregnancies as overweight
or obese, respectively. Women should be encouraged to follow any intervention that is convenient and
available, as the effects on GWG were similar for diet, physical activity and mixed-approach interventions.
Similarly, it is not essential to configure services to target pregnant women based on age, ethnicity or
underlying medical risk factors to deliver the intervention.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Health-care professionals should reassure women that lifestyle interventions do not increase the risk of
adverse outcomes in their unborn child. The potential for benefit in improving maternal outcomes needs
discussion. Pregnant women should be informed of the absence of relationship between prespecified
weight-gain targets and composite adverse outcomes.
Research recommendations
The i-WIP Collaborative Network has provided a platform for lead researchers in this field to prioritise
outcomes, standardise variables, plan future studies and influence public policies.19,20 Further evaluation is
needed to assess the differential effects of the interventions for individual maternal and fetal/neonatal
outcomes. Addition of data from non-IPD studies to IPD meta-analysis for individual outcomes would be
more informative than the comparison of IPD with only published aggregate data. Compliance with the
IOM-recommended weight-gain targets and individual outcomes would add to the current evidence base.
Although interventions in pregnancy have been widely studied, very few have focused on the optimisation
of the health of the mother in early pregnancy. Future studies will need to focus on interventions that
optimise the health of women in the pre-pregnancy period. Such a strategy should also target women in
the postpartum period, to ensure that their health status is optimal on entering a subsequent pregnancy.
Long-term follow-up of women and their children exposed to the interventions should be prioritised as a
research topic by funders and researchers. Health service delivery research is required to identify the ideal
way to effectively deliver diet- and lifestyle-based interventions.
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Appendix 1 Outcomes prioritised in Delphi survey
TABLE 42 List of maternal and neonatal outcomes considered to be relevant to patient care when evaluating
dietary and lifestyle interventions in pregnancy
Outcomes
Maternal Fetal
Weight gain in pregnancy SGA
Postpartum weight retention LGA
Interpregnancy weight gain Skinfold thickness
GDM Fetal fat mass (%)
PE/PIH Abdominal circumference
Postpartum haemorrhage Head circumference
Prolonged labour Ponderal index (g/cm3 × 100)
Preterm delivery Neonate length/crown–heel length
Induction of labour Head-to-abdomen ratio
Prelabour rupture of membranes Birthweight-related outcomes, such as BMI
Caesarean section Hypoglycaemia
Instrumental delivery Hyperbilirubinaemia
Perineal trauma IUD
Puerperal pyrexia (≥ 38 °C) Respiratory distress syndrome
Miscarriage Admission to the NICU
Need for resuscitation at delivery Shoulder dystocia
Antepartum haemorrhage ≥ 1 perinatal complication
Thromboembolism Birth trauma number
Admission to high-dependency unit/intensive therapy unit Neural tube defect
Anaemia Cleft lip or palate or both
Infections Other congenital abnormalities
Postnatal infections Apgar score
Postnatal depression Cardiotocograph abnormalities
Anxiety Abnormal cord pH
Quality of life Long-term neurological sequelae
Physical activity Cord abnormalities
Dietary behaviour Long-term metabolic sequelae
Body fat (%)
Back pain
Breastfeeding
Threatened abortion
Failed instrumental delivery
Coronary artery disease
Non-infective respiratory distress
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TABLE 43 Maternal, and fetal and neonatal outcomes ranked by the Delphi panel
Items
Round
First Second
Median Interquartile range Median Interquartile range
Maternal outcomes
PEa 8.5 1 9 0
PIHa 8.5 1 9 1
GDM 8.5 1 9 0
Preterm delivery 7.5 1 8 2
Caesarean section: electivea 8 2 8 1
Caesarean section: emergencya 8 2 8 0
Fetal outcome
IUD 9 1.25 9 0
SGA 8 1 8 1
LGA 8 1 8 1
Admission to the NICU 8 1 8 0
a Combined into one outcome.
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Appendix 2 Search strategies
TABLE 44 Search strategy for MEDLINE (via Ovid)
Item Term
1 Pregnancy/
2 pregnan*.tw.
3 Gravidity/
4 gravid*.tw.
5 gestation*.tw.
6 Pregnant Women/
7 pregnant wom#n.tw.
8 (child adj3 bearing).tw.
9 childbearing.tw.
10 matern*.tw.
11 or/1-10
12 Weight Gain/ph [Physiology]
13 weight gain*.tw.
14 Weight Loss/ph [Physiology]
15 weight loss*.tw.
16 weight change*.tw.
17 Obesity/dh, me, ph, pc, px, th [Diet Therapy, Metabolism, Physiology, Prevention & Control, Psychology, Therapy]
18 obes*.tw.
19 Adiposity/ph [Physiology]
20 adipos*.tw.
21 Overweight/dh, me, ph, pc, px, th [Diet Therapy, Metabolism, Physiology, Prevention & Control, Psychology,
Therapy]
22 overweight*.tw.
23 Body Mass Index/
24 bmi.tw.
25 or/12-24
26 exp Randomized Controlled Trial/
27 “randomized controlled trial”.pt.
28 “controlled clinical trial”.pt.
29 (random$ or placebo$).tw,sh.
30 ((singl$ or double$ or triple$ or treble$) and (blind$ or mask$)).tw,sh.
31 single-blind method/
32 double-blind method/
33 or/26-32
continued
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TABLE 44 Search strategy for MEDLINE (via Ovid) (continued )
Item Term
34 11 and 25 and 33
35 exp Animals/
36 (rat$ or mouse or mice or hamster$ or animal$ or dog$ or cat$ or bovine or sheep or lamb$).af.
37 35 or 36
38 Humans/
39 human$.tw,ot,kf.
40 37 or 38
41 37 not (37 and 40)
42 34 not 41
TABLE 45 Search strategy for The Cochrane Library
Item Terms
#1 (Pregnancy):ti,ab,kw
#2 pregnan*
#3 Gravidity
#4 gravid*
#5 gestation*
#6 “Pregnant Women”
#7 childbearing
#8 matern*
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 (Weight Gain):ti,ab,kw
#11 (Weight Loss):ti,ab,kw
#12 weight loss*
#13 weight change*
#14 (Obesity):ti,ab,kw
#15 obes*
#16 Adiposity:ti,ab,kw
#17 adipos*
#18 Overweight:ti,ab,kw
#19 overweight*
#20 “Body Mass Index”
#21 BMI
#22 (#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21)
#23 (#9 AND #22)
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Appendix 3 International Weight Management in
Pregnancy individual participant data meta-analysis
project variables
TABLE 46 Variables
Variable label Variable type
Variable
format Variable range
Height (cm) Numeric 999 999 =missing
Pre-pregnancy weight (kg) Numeric 999.9 999 =missing
Pre-pregnancy BMI (kg/m2) Numeric 99.99 99=missing
Early pregnancy weight (kg) Numeric 999.9 999 =missing
Early pregnancy BMI (kg/m2) Numeric 99.99 99=missing
Gestational age at baseline (weeks) Numeric 99 0–50, 99 =missing
Gestational age at baseline (days) Numeric 9 0–6, 9=missing
Gestational age at follow-up (weeks) Numeric 99 0–50, 99 =missing
Gestational age at follow-up (days) Numeric 9 0–6, 9=missing
Follow-up weight (kg) Numeric 999.9 999 =missing
Follow-up BMI (kg/m2) Numeric 99.99 99=missing
Total weight gain (kg) Numeric 999.9 999 =missing
Weight post delivery (kg) Numeric 999.9 999 =missing
Babies birthweight (g) Numeric 9999 9999 =missing
Age (years) Numeric 99.9 99=missing
Land of birth String
Race/ethnicity Numeric categorical 9 1= Caucasian, 2 = Asian,
3= Afro-Caribbean, 4= Central/
South American, 5=Middle
Eastern, 6= other, 9= nk
Education mother, detail String
Education mother, low/medium/high Numeric categorical 9 1= low, 2=middle, 3 = high,
9= nk
Current smoker Numeric categorical 9 0= no, 1 = yes, 9= nk
Ex-smoker (pre pregnancy) Numeric categorical 9 0= no, 1 = yes, 9= nk
Allocation Numeric categorical 9 0= control, 1 = intervention1,
2= intervention2, 9= nk
Unit of randomisation String For example participantid,
centre id . . .
Adherence Numeric categorical 9 2= control group, 1= yes, 0= no,
9= nk
Number of fetuses Numeric categorical 9 1= singleton, 2= twin or more,
9=missing
continued
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TABLE 46 Variables (continued )
Variable label Variable type
Variable
format Variable range
Gestational age at delivery (weeks) Numeric 99 99=missing
Mode of delivery Numeric categorical 9 1= nvd, 2= instrumental/vacuum/
forceps, 3 = cs, 9= nk
Number of times giving birth before
this pregnancy
Numeric 99 99=missing
Previous miscarriages Numeric categorical 9 0= no, 1 = yes, 9= nk
Gravidity (number of times pregnant) Numeric 99 99=missing
Obesity (BMI of ≥ 30 kg/m2) Numeric categorical 9 0= no, 1 = yes, 9= nk
Previous large baby (≥ 4.5 kg) Numeric categorical 9 0= no, 1 = yes, 9= nk
Previous GDM Numeric categorical 9 0= no, 1 = yes, 9= nk
Family history of DM Numeric categorical 9 0= no, 1 = yes, 9= nk
Baseline GDM Numeric categorical 9 0= no, 1 = yes, 9= nk
Baseline DM Numeric categorical 9 0= no, 1 = yes, 9= nk
Baseline PIH Numeric categorical 9 0= no, 1 = yes, 9= nk
Baseline hypertension Numeric categorical 9 0= no, 1 = yes, 9= nk
Exercise detail String
GDM test value Numeric 999.9 999 =missing
GDM test unit Text
Type of GDM test Text
GDM Numeric categorical 9 0= no, 1 = yes, 9= nk
PIH Numeric categorical 9 0= no, 1 = yes, 9= nk
PE Numeric categorical 9 0= no, 1 = yes, 9= nk
Preterm delivery Numeric categorical 9 0= no, 1 = yes, 9= nk
Caesarean section Numeric categorical 9 0= no, 1 = cs unspecified,
2= elective, 3= emergency,
9= nk
IUD Numeric categorical 9 0= no, 1 = yes, 9= nk
SGA Numeric categorical 9 0= no, 1 = yes, 9= nk
LGA Numeric categorical 9 0= no, 1 = yes, 9= nk
Admission to the NICU Numeric categorical 9 0= no, 1 = yes, 9= nk
cs, Caesarean section; ID, identification; nk, not known; nvd, normal vaginal delivery.
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Appendix 4 Variables recoding
TABLE 47 Standardisation of IPD ethnicity data
Caucasian (including
Russia and Australia) Asian Afro-Caribbean
Central/South
American
Middle Eastern
(including Iran
and Turkey) Other
Afro-Caribbean Malaysia Tunisia Argentina Iran Aboriginal
Australia Nepal Uganda Brazil Iraq Australia/
Aboriginal
Australian – Aboriginal Pakistan Unclassified
(other)
Brazil Black Israel Fiji
Austria Pakistani Zimbabwe Brazil Pardo Lebanon New Zealand
Belgian/Dutch Philippines Maghreb Brazil White Middle Eastern Non-Caucasian
Belgium South East Asian Chile Turkey Other
Bosnia Sri Lanka Colombia Turkish
Bosnia-Herzegovina Sri-Lanka Columbia
Bulgaria Taiwan El Salvador
Caucasian Thailand Mexico
Caucasian, excluding
Turkey and Morocco
Unclassified
(other)
Croatia Uzbekistan
Czech Vietnam
Denmark Japan
East European
England
European
Finland/England/
Sweden/Russia
France
Germany
Greece
Hungary
Iceland
Iraq
Italian
Italy
Kosovo
Latvia
Lebanon
North American White
Norway
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TABLE 47 Standardisation of IPD ethnicity data (continued )
Caucasian (including
Russia and Australia) Asian Afro-Caribbean
Central/South
American
Middle Eastern
(including Iran
and Turkey) Other
Other White
Pakistan
Poland
Romania
Russia
Serbia
Slovakia
Spain
Sweden
The Faroes
Turkey
Ukraine
Unclassified (other)
White Irish
Yugoslavia
Caucasian
We assumed IPD data to be clean and, therefore, individual items (in italic) may seem to be in the wrong category.
We assumed IPD data to be clean and, therefore, individual items may seem to be in the wrong category.
However, if the study already had categories that matched our structure, then we used those rather than
the additional details provided.
TABLE 48 Standardisation of IPD education data
Low Medium High
< 12 years (preparatory school or
occupational school)
12 years (high school) Vocational training school
< 4 years of study 4–8 years of study < 4 years additional education
First degree A-level (or equivalent) > 12 years (university or equivalent to it)
Grammar school ≤ 10 years GCE (or equivalent) > 8 years of study
LBO General secondary school ≥ 4 years additional education
Less than high school General upper secondary education College/university < 4 years
Low HAVO/VWO Further education 1–2 years
Low (basic or secondary education) High school Graduate degree
None High school/grammar school Graduated, 14 years
Preliminary, 5 years High school diploma Graduated, 16 years
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TABLE 48 Standardisation of IPD education data (continued )
Low Medium High
Preliminary, 9 years High school, 12 years HBO
Primary Intermediate secondary school High (university degree)
Primary and secondary school MBO Higher degree
Primary education Medium (polytechnic education) Postgraduate education
Primary or less Secondary Postgraduate
Primary school Secondary school 12 years Tertiary
VMBO Upper secondary school Tertiary education 3–4 years
(Bachelor level)
Year 10 or below Vocational upper secondary
education
Undergraduate
Year 11 or equivalent Year 12 or equivalent University
Elementary school Complete secondary University degree
Grade school (< 6 years) High school University/university college < 4 years
Junior high school (7–9 years) High school (13 years) University/university college > 4 years
Less than primary school High school (10–12 years) Vocational qualification
Less than primary school Medium-length education WO
Middle School maximum 10 years, additional
education
Year 12 or equivalent
Middle school (8 years) Technical, additional education Bachelors level
Primary school Until 18 year, possible a speciality of
1/2 year
College (university)
School maximum 10 years, education
unfinished
Vocational training College/university degree
Some secondary College/university 4+ years
Technical/high school, education
unfinished
Complete third level
Graduate or professional education
Graduated
High school, additional education
Masters level or higher
Post graduation level
Same college (< 4 years)
Some third-level university
GCE, General Certificate of Education; HAVO/VWO, hoger algemeen voortgezet onderwijs & voorbereidend
wetenschappelijk onderwijs; HBO, hoger beroepsonderwijs; LBO, laag beroepsonderwijs; MBO, middelbaar
beroepsonderwijs; VMBO, voorbereidend middelbaar beroepsonderwijs; WO, wetenschappelijk onderwijs.
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TABLE 49 Standardisation of IPD baseline activity data
Level of activity
No exercise/sedentary At least some activity
< 600 MET minutes/week ≥ 10,000 steps/day
< 600 MET hours/week ≥ 600MET minutes/week
Accelerometer < 2.5 hours/week ≥ 600MET hours/week
Does not attend gym Accelerometer ≥ 2.5 hours/week
Does not exercise regularly at inclusion Does attend gym
Fewer than 10,000 steps/day Exercise regularly at inclusion
Low Handiwork
PPAQ < 1000 cal Hard
Sedentary High
Sedentary work Light–moderate
Work mainly sedentary Moderate
Completely inactive Moderate–hard
Completely sedentary PPAQ ≥ 1000 cal
Lying Physically active
Sedentary Work in movement
Sedentary work Work standing
Sitting Work standing and in movement
Some activity occasionally Active
Active (PPAQ)
Active (exercise two or three times a week)
Active work
High-performance athlete
Housewife
Professional athlete
Something active
Standing
Very active
Very active (regular exercise four or five times a week)
Walking
MET, metabolic equivalent of task; PPAQ, Paffenbarger Physical Activity Questionnaire.
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Appendix 5 Details of trials with unavailable
individual participant data
TABLE 50 Eligible trials for without access to IPD
Study (first author and
reference number) Reason
Intervention
group Country Sample size
Asbee et al.28 No response Mixed USA 100
Barakat et al.42 Conflict of interest Exercise Spain 100
Barakat et al.43 Conflict of interest Exercise Spain 510
Bechtel-Blackwell30 No response Diet USA 46
Briley et al.31 No response Diet USA 20
aCallaway et al.145 Not approached Exercise Australia 50
Clapp et al.44 Data loss Exercise USA 51
Deveer et al.32 No response Diet Turkey 100
Garshasbi et al.33 No response Exercise Iran 212
Gomez-Tabarez et al.34 No response Diet Colombia 60
Hopkins et al.146 Contact loss Exercise New Zealand 81
Huang et al.35 No response Mixed Taiwan 125
Jackson et al.147 Contact loss Mixed USA 321
Korpi-Hyövälti et al.39 Lack of time Diet Finland 54
Lee et al.45 Data loss Exercise UK 370
Marquez-Sterling et al.148 Contact loss Exercise USA 15
Polley et al.36 No response Mixed USA 110
Quinlivan et al.41 Data sharing issues Diet Australia 132
Santos et al.37 No response Exercise Australia 72
Sedaghati et al.38 No response Exercise Iran 90
Thornton et al.40 Lack of time Diet USA 232
Vesco et al.149 Contact loss Mixed USA 114
Ramírez-Vélez et al.59 Not approached Exercise Colombia 64
Ramírez-Vélez60 Not approached Exercise Colombia 20
Badrawi et al.29 No response Diet Egypt 100
Cordero et al.47 Not approached Exercise Spain 342
de Oliveria Melo et al.47 Not approached Exercise Brazil 187
Di Carlo et al.50 Not approached Diet Italy 154
Hawkins et al.51 Not approached Mixed USA 68
Hui et al.52 Not approached Mixed Canada 113
Jing et al.53 Not approached Mixed China 262
Kong et al.54 Not approached Exercise USA 42
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TABLE 50 Eligible trials for without access to IPD (continued )
Study (first author and
reference number) Reason
Intervention
group Country Sample size
Murtezani et al.57 Not approached Exercise Republic of Kosovo 72
Price et al.58 Not approached Exercise USA 91
Li et al.57 Not approached Mixed China 239
Ronnberg et al.61 Not approached Exercise Sweden 445
Bisson et al.46 Not approached Exercise Canada 37
Mujsindi et al.47 Not approached Mixed USA 79
a Data from secondary publication Dekker Nitert et al.49
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Appendix 6 Clinical characteristics of the
randomised controlled trials
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Appendix 8 Sensitivity analysis for the main
outcomes
TABLE 53 Summary of sensitivity analyses for GWG as an outcome
Sample size (number of studies)
Group, mean GWG (SD)
Adjusted differencea (95% CI) 95% PIControl Intervention
Primary analysis for GWG
9320 (33) 10.8 (5.4) 10.1 (5.4) –0.70 (–0.92 to –0.48) –1.24 to –0.16
Analysis including aggregate data
12,895 (60) 11.5b 10.5b –1.13 (–1.58 to –0.68) –4.10 to 1.83
Analysis excluding studies rated as being at a high risk of bias
5585 (15) 11.5 (5.3) 10.9 (5.2) –0.67 (–0.95 to –0.38) –1.14 to –0.19
Analysis excluding participants with gestational age at follow-up < 37 weeks
5324 (28) 12.2 (5.3) 11.4 (5.4) –0.91 (–1.17 to –0.66) –1.17 to –0.66
Analysis excluding women not adherent to intervention
8565 (33) 10.8 (5.4) 10.3 (5.4) –0.76 (–1.00 to –0.52) –1.31 to –0.21
Analysis using change in BMI (kg/m2)
9238 (31) 3.9 (2.0) 3.6 (2.0) –0.3 (–0.39 to –0.21) –0.60 to 0.00
Intervention groups
Analysis including only studies with diet-based interventions
1168 (4) 11.0 (4.8) 10.2 (4.4) –0.72 (–1.48 to 0.04) –1.75 to 0.30
Analysis including only studies with physical activity-based interventions
2915 (15) 10.8 (5.3) 9.8 (4.4) –0.73 (–1.11 to –0.34) –1.50 to 0.05
Analysis including only studies with mixed approach
5369 (15) 10.6 (5.9) 10.2 (6.0) –0.71 (–1.10 to –0.31) –1.42 to 0.01
a Model accounting for baseline weight and clustering effect.
b Not estimable.
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TABLE 54 Sensitivity analyses for primary outcome composite maternal events
Sample size
(number of studies)
Group, n (%)
Summary ORa (95% CI) 95% PIControl Intervention group
Primary analysis for composite maternal outcome
8852 (24) 1837/4227 (43.5) 1896/4624 (41.0) 0.90 (0.79 to 1.03) 0.68 to 1.20
Analysis excluding studies rated as being at a high risk of bias
4873 (10) 1009/2421 (41.7) 979/2452 (39.9) 0.91 (0.77 to 1.08) 0.70 to 1.19
Analysis excluding women not adherent to intervention
7949 (24) 1837/4227 (43.5) 1527/3722 (41.0) 0.92 (0.80 to 1.06) 0.66 to 1.30
Analysis of the intervention effects on the individual components of composite maternal outcome
PE or PIH
9618 (22) 423/4600 (9.2) 432/5018 (8.6) 0.95 (0.78 to 1.16) 0.69 to 1.31
Pooled-effect GDM
9427 (27) 571/4510 (12.7) 584/4917 (11.9) 0.89 (0.72 to 1.10) 0.49 to 1.60
Preterm delivery
11,676 (32) 345/5631 (6.1) 332/6045 (5.5) 0.94 (0.78 to 1.13) 0.78 to 1.13
Caesarean section
11,410 (32) 1506/5500 (27.4) 1527/5910 (25.8) 0.91 (0.83 to 0.99) 0.83 to 1.99
Intervention groups
Analysis including only studies with diet-based interventions
397 (3) 84/218 (38.5) 42/179 (23.5) 0.60 (0.20 to 1.75) 0.02 to 14.27
Analysis including only studies with physical activity-based interventions
2311 (9) 367/1115 (32.9) 346/1196 (28.9) 0.81 (0.61 to 1.09) 0.48 to 1.37
Analysis including only studies with mixed approach
6259 (13) 1438/3009 (47.8) 1508/3250 (46.4) 0.97 (0.84 to 1.12) 0.82 to 1.13
a Model accounting for clustering effect.
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TABLE 55 Sensitivity analyses for primary outcome composite fetal events
Sample size (number of studies)
Group, n (%)
Summary ORa (95% CI) 95% PIControl Intervention group
Primary analysis for fetal and neonatal composite outcome
7981 (18) 951/3802 (25.0) 1007/4179 (24.1) 0.94 (0.83 to 1.08) 0.74 to 1.21
Two-stage meta-analysis fetal composite excluding studies rated as being at a high risk of bias
3708 (6) 467/1855 (25.2) 417/1853 (22.5) 0.86 (0.71 to 1.06) 0.69 to 1.07
Two-stage meta-analysis fetal composite excluding non-adherent participants
6875 (18) 951/3802 (25.0) 720/3073 (23.4) 0.94 (0.83 to 1.06) 0.83 to 1.06
Analysis of the intervention effects on the individual components of fetal and neonatal composite outcome
IUD
Insufficient data – – – –
SGA
11,666 (33) 632/5633 (11.2) 709/6033 (11.8) 1.06 (0.94 to 1.20) 0.94 to 1.20
LGA
12,047 (34) 759/5811 (13.1) 744/6236 (11.9) 0.90 (0.76 to 1.07) 0.63 to 1.30
Admissions to the NICU
8140 (16) 279/3865 (7.2) 302/4275 (7.1) 1.01 (0.84 to 1.23) 0.84 to 1.23
Intervention groups
Analysis including only studies with diet-based interventions
346 (2) 48/180 (26.7) 34/166 (20.5) 0.71 (0.03 to 18.23) –
Analysis including only studies with physical activity-based interventions
1274 (5) 143/641 (22.3) 138/633 (21.8) 0.99 (0.67 to 1.46) 0.64 to 1.54
Analysis including only studies with mixed approach
6494 (12) 797/3114 (25.6) 835/3380 (24.7) 0.95 (0.81 to 1.11) 0.71 to 1.27
a Model accounting for clustering effect.
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Appendix 9 Results of aggregate meta-analyses
Maternal outcomes
Study or subgroup Events Total
Experimental
Events Total
Control Odds ratio
M–H, random, 95% CI
Odds ratio
M–H, random, 95% CIWeight (%)
Only aggregate data
Barakat43 2013
Callaway145 2010a
Hui52 2014
Jing53 2015
Kong54 2014
Korpi-Hyövälti39 2012
Polley36 2002
Price58 2012
Quinlivan41 2011
Thornton40 2009
Vesco149 2014
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 8.77, df = 10 (p = 0.55); I2 = 0%
Test for overall effect: z = 3.40 (p = 0.0007)
IPD available
Barakat42 2012
Barakat153 2012b
Bogaerts64 2013b
Dodd72 2014
Guelinckx66 2010c
Harrison73 2013
Hui91 2012
Jeffries92 2009
Luoto62 2011d
Oostdam75 2012
Petrella74 2014
Phelan93 2011
Poston68 2015
Rauh63 2013e
Renault69 2014
Ruiz87 2013
Stafne88 2012
Vinter70 2011
Walsh78 2012
Wolff71 2008
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.08; χ2 = 29.24, df = 17 (p = 0.03); I2 = 42%
Test for overall effect: z = 1.51 (p = 0.13)
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.08; χ2 = 44.85, df = 28 (p = 0.02); I2 = 38%
Test for overall effect: z = 2.61 (p = 0.009)
Test for subgroup differences: χ2 = 2.71, df = 1 (p = 0.10); I2 = 63.2%
41
5
1
26
1
3
2
3
4
11
6
103
255
22
57
131
19
27
61
43
67
124
58
864
61
3
3
37
1
1
3
4
17
19
7
156
255
19
56
131
23
27
59
48
65
133
60
876
7.8
1.4
0.7
6.1
0.5
0.7
1.1
1.4
2.4
4.2
2.4
28.5
0.61 (0.39 to 0.95)
1.57 (0.32 to 7.66)
0.32 (0.03 to 3.13)
0.63 (0.35 to 1.12)
1.22 (0.07 to 20.94)
3.25 (0.32 to 33.41)
0.63 (0.10 to 3.93)
0.82 (0.17 to 3.91)
0.18 (0.06 to 0.57)
0.58 (0.27 to 1.28)
0.87 (0.28 to 2.77)
0.62 (0.47 to 0.81)
0
6
16
148
5
27
2
13
44
7
7
19
160
8
8
16
25
9
12
0
480
50
160
142
1108
130
121
112
148
0
62
33
201
783
0
284
481
429
180
394
28
4846
3
12
7
120
1
35
3
10
29
11
16
13
172
9
7
30
18
8
18
3
487
50
160
63
1104
65
107
112
138
0
59
30
200
772
0
141
481
426
180
406
38
4532
0.4
2.9
3.3
10.5
0.8
6.0
1.1
3.7
2.9
2.6
4.6
10.7
2.8
5.6
5.6
3.1
4.5
0.4
71.5
0.13 (0.01 to 2.67)
0.48 (0.18 to 1.31)
1.02 (0.40 to 2.61)
1.26 (0.98 to 1.63)
2.56 (0.29 to 22.38)
0.59 (0.33 to 1.06)
0.66 (0.11 to 4.03)
1.23 (0.52 to 2.91)
Not estimable
0.56 (0.20 to 1.55)
0.24 (0.08 to 0.71)
1.50 (0.72 to 3.13)
0.90 (0.70 to 1.14)
Not estimable
0.55 (0.20 to 1.56)
0.52 (0.28 to 0.96)
1.40 (0.75 to 2.61)
1.13 (0.43 to 3.00)
0.68 (0.32 to 1.42)
0.18 (0.01 to 3.59)
0.84 (0.84 to 1.05)
583
5710
643
5408 100.0 0.77 (0.63 to 0.94)
1.00
Favours (control)Favours (experimental)
10.00 100.000.100.01
FIGURE 23 Outcome: GDM. a, Data from the secondary publication Dekker Nitert et al.;49 b, combined active and
passive; c, combined active and passive; d, cluster RCT; e, cluster RCT. df, degrees of freedom; M–H, Mantel–Haenszel.
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Study or subgroup Events Total
Experimental
Events Total
Control Odds ratio
M–H, random, 95% CI
Odds ratio
M–H, random, 95% CIWeight (%)
Only aggregated data
Barakat43 2013
de Oliveria Melo48 2012
Kong54 2014
Thornton40 2009
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 1.74, df = 3 (p = 0.63); I2 = 0%
Test for overall effect: z = 0.68 (p = 0.50)
IPD available
Bogaerts64 2013a
Bogaerts64 2013b
Dodd72 2014c
Dodd72 2014d
Guelinckx66 2010e
Guelinckx66 2010f
Haakstad82 2011g
Jeffries92 2009h
Jeffries92 2009i
Khoury76 2005j
Luoto62 2011k
Petrella74 2014
Phelan93 2011l
Polley36 2002
Poston68 2015
Renault69 2014m
Ruiz87 2013
Stafne88 2012
Vesco149 2014
Vinter70 2011
Wolff71 2008n
Wolff71 2008o
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 15.21, df = 15 (p = 0.44); I2 = 1%
Test for overall effect: z = 1.26 (p = 0.21)
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 17.05, df = 19 (p = 0.59); I2 = 0%
Test for overall effect: z = 1.37 (p = 0.17)
Test for subgroup differences: χ2 = 0.10, df = 1 (p = 0.75); I2 = 0%
5
6
1
7
19
255
114
19
124
512
4
5
0
11
20
255
57
23
133
468
1.7
1.9
0.3
3.1
6.9
1.25 (0.33 to 4.73)
0.58 (0.17 to 1.98)
3.81 (0.15 to 99.08)
0.66 (0.25 to 1.77)
0.80 (0.42 to 1.53)
9
19
101
56
2
24
1
6
4
7
14
1
20
2
27
16
13
16
5
23
0
1
280
142
142
1108
1108
130
130
52
148
148
141
0
33
201
61
783
284
481
429
58
180
28
28
4259
4
6
94
53
1
14
1
2
1
8
10
7
22
3
27
12
30
16
6
28
1
4
279
63
63
1104
1104
65
65
53
138
138
149
0
30
200
59
772
141
481
426
60
180
38
38
3959
3.1
34.0
5.4
0.4
0.0
0.6
2.7
0.6
7.2
0.9
10.0
4.9
6.7
5.9
1.9
8.3
0.0
0.6
93.1
Not estimable
1.47 (0.56 to 3.87)
1.08 (0.80 to 1.45)
Not estimable
Not estimable
0.82 (0.39 to 1.73)
1.02 (0.06 to 16.74)
2.87 (0.57 to 14.48)
3.81 (0.42 to 34.47)
0.92 (0.32 to 2.61)
Not estimable
0.10 (0.01 to 0.89)
0.89 (0.47 to 1.70)
0.63 (0.10 to 3.93)
0.99 (0.57 to 1.70)
0.64 (0.29 to 1.40)
0.42 (0.22 to 0.81)
0.99 (0.49 to 2.01)
0.85 (0.24 to 2.95)
0.80 (0.44 to 1.44)
0.44 (0.02 to 11.17)
0.31 (0.03 to 2.98)
0.84 (0.74 to 1.07)
299
4771
299
4427 100.0 0.89 (0.75 to 1.05)
1.00
Favours (control)Favours (experimental)
10.00 100.000.100.01
FIGURE 24 Outcome: PE or PIH. a, PE: combined active and passive; b, PIH: combined active and passive; c, PIH;
d, PE; e, PE; f, PIH: combined active and passive; g, hypertension in exercise group, PE in control; h, PE; i, PIH; j, PE;
k, cluster RCT; l, maternal hypertension; m, two intervention arms combined; n, PE; o, PIH. df, degrees of freedom;
M–H, Mantel–Haenszel.
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Study or subgroup Events Total
Experimental
Events Total
Control Odds ratio
M–H, random, 95% CI
Odds ratio
M–H, random, 95% CIWeight (%)
Only aggregated data
Althuizen90 2013
Barakat42 2012a
Briley31 2002
Deveer32 2013
Kong54 2014
Price58 2012
Li55 2014
Santos37 2005
Thornton40 2009
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 3.49, df = 8 (p = 0.90); I2 = 0%
Test for overall effect: z = 0.65 (p = 0.52)
IPD available
Baciuk79 2008
Barakat80 2008
Dodd72 2014
Haakstad82 2011
Jeffries92 2009
Khoury76 2005
Petrella74 2014
Phelan93 2011
Polley36 2002
Prevedel86 2003
Rauh63 2013
Renault69 2014a
Ruiz87 2013
Vesco149 2014
Walsh78 2012
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.14; χ2 = 18.70, df = 13 (p = 0.13); I2 = 30%
Test for overall effect: z = 0.99 (p = 0.32)
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 22.23, df = 22 (p = 0.45); I2 = 1%
Test for overall effect: z = 1.88 (p = 0.06)
Test for subgroup differences: χ2 = 0.01, df = 1 (p = 0.93); I2 = 0%
6
9
0
1
0
1
6
2
3
28
123
160
10
50
19
43
123
46
124
698
7
10
1
4
1
0
5
1
5
34
123
160
10
50
23
48
116
46
133
709
4.3
6.2
0.5
1.1
0.5
0.5
3.6
0.9
2.6
20.2
0.85 (0.28 to 2.61)
0.89 (0.35 to 2.26)
0.30 (0.01 to 8.33)
0.23 (0.03 to 2.18)
0.38 (0.01 to 9.99)
3.42 (0.14 to 86.29)
1.14 (0.34 to 3.84)
2.05 (0.18 to 23.38)
0.63 (0.15 to 2.71)
0.84 (0.50 to 1.41)
2
2
62
2
3
1
0
16
7
3
4
12
9
4
3
126
34
80
1108
52
148
141
33
201
61
29
0
284
481
58
394
3104
3
3
83
1
4
11
10
20
5
1
5
6
5
1
8
161
37
80
1104
53
138
149
30
200
59
31
0
141
481
60
406
2969
1.6
1.6
41.6
0.9
2.4
1.3
0.7
11.1
3.7
1.0
5.3
4.4
1.1
3.0
79.8
0.71 (0.11 to 4.52)
0.66 (0.11 to 4.05)
0.73 (0.52 to 1.02)
2.08 (0.18 to 23.67)
0.69 (0.15 to 3.15)
0.09 (0.01 to 0.70)
0.03 (0.00 to 0.52)
0.78 (0.39 to 1.55)
1.40 (0.42 to 4.69)
3.46 (0.34 to 35.34)
Not estimable
0.99 (0.36 to 2.70)
1.82 (0.60 to 5.46)
4.37 (0.47 to 40.33)
0.38 (0.10 to 1.45)
0.82 (0.55 to 1.22)
154
3802
195
3678 100.0 0.80 (0.63 to 1.01)
1.00
Favours (control)Favours (experimental)
10.00 100.000.100.01
FIGURE 25 Outcome: preterm birth. a, Two intervention arms combined. df, degrees of freedom;
M–H, Mantel–Haenszel.
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Study or subgroup Events Total
Experimental
Events Total
Control Odds ratio
M–H, random, 95% CI
Odds ratio
M–H, random, 95% CIWeight (%)
Only aggregate available
Althuizen90 2013
Asbee28 2009
Barakat42 2012a
Barakat43 2013
Callaway145 2010b
Deveer32 2013
Gomez-Tabarez34 1994
Hui52 2014
Khaledan83 2010
Kong54 2014
Lee45 1996
Marquez-Sterling148 2000
Polley36 2002
Price58 2012
Ramírez-Vélez59 2011
Thornton40 2009
Vesco149 2014
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.09; χ2 = 23.54, df = 16 (p = 0.10); I2 = 32%
Test for overall effect: z = 1.65 (p = 0.10)
IPD available
Baciuk79 2008
Barakat81 2011
Barakat42 2012
Bogaerts64 2013a
Dodd72 2014
Guelinckx66 2010c
Hui91 2012
Jeffries92 2009
Nascimento84 2011
Oostdam75 2012
Perales85 2015
Perales85 2015a
Petrella74 2014
Phelan93 2011
Poston68 2015
Rauh63 2013d
Renault69 2014e
Ruiz87 2013
Stafne88 2012
Vinter70 2011
Wolff71 2008
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 12.39, df = 19 (p = 0.87); I2 = 0%
Test for overall effect: z = 1.50 (p = 0.13)
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 36.89, df = 36 (p = 0.43); I2 = 2%
Test for overall effect: z = 2.15 (p = 0.03)
Test for subgroup differences: χ2 = 0.99, df = 1 (p = 0.32); I2 = 0%
16
8
22
33
9
16
14
0
11
5
26
3
4
2
7
91
21
288
123
57
160
255
19
50
30
57
20
19
182
9
61
43
33
124
58
1300
22
12
35
42
4
20
12
2
16
9
25
2
10
10
3
83
26
333
123
43
160
255
16
50
30
56
24
23
177
6
59
48
31
133
60
1294
1.9
0.9
2.7
3.7
0.4
1.4
0.9
0.1
0.6
0.5
2.6
0.2
0.6
0.4
0.4
3.2
1.7
22.4
0.69 (0.34 to 1.38)
0.42 (0.15 to 1.15)
0.57 (0.32 to 1.02)
0.75 (0.46 to 1.23)
2.70 (0.64 to 11.47)
0.71 (0.31 to 1.60)
1.31 (0.47 to 3.65)
0.19 (0.01 to 4.04)
0.61 (0.18 to 2.08)
0.56 (0.15 to 2.08)
1.01 (0.56 to 1.83)
1.00 (0.11 to 8.95)
0.34 (0.10 to 1.17)
0.19 (0.04 to 0.90)
2.51 (0.59 to 10.76)
1.66 (0.98 to 2.82)
0.74 (0.35 to 1.56)
0.80 (0.61 to 1.04)
12
7
12
34
197
20
2
41
25
7
14
11
11
57
271
47
83
93
45
40
2
984
34
40
50
142
1108
130
112
148
40
62
101
122
33
201
783
0
284
481
429
180
28
4508
17
10
6
19
214
7
3
30
29
8
19
14
9
67
274
33
50
93
50
39
3
961
37
40
50
63
1104
65
112
138
42
59
83
177
30
200
772
0
141
481
426
180
38
4238
1.0
0.8
0.8
2.1
17.3
1.1
0.3
3.1
1.1
0.8
1.6
1.4
0.8
5.0
18.1
0.0
4.9
8.5
4.9
3.7
0.3
77.6
0.64 (0.25 to 1.67)
0.64 (0.22 to 1.88)
2.32 (0.79 to 6.76)
0.73 (0.38 to 1.41)
0.90 (0.73 to 1.11)
1.51 (0.60 to 3.77)
0.66 (0.11 to 4.03)
1.38 (0.80 to 2.37)
0.75 (0.30 to 1.87)
0.81 (0.27 to 2.40)
0.54 (0.25 to 1.16)
1.15 (0.51 to 2.63)
1.17 (0.40 to 3.38)
0.79 (0.51 to 1.20)
0.96 (0.78 to 1.18)
0.60 (0.34 to 1.06)
0.75 (0.49 to 1.15)
1.00 (0.73 to 1.38)
0.88 (0.57 to 1.35)
1.03 (0.63 to 1.70)
0.90 (0.14 to 5.76)
0.92 (0.83 to 1.02)
1272
5808
1294
5532 100.0 0.90 (0.82 to 0.99)
1.00
Favours (control)Favours (experimental)
10.00 100.000.100.01
FIGURE 26 Outcome: any Caesarean section. a, Combined active and passive; b, data from the secondary
publication Dekker Nitert et al.;49 c, combined active and passive; d, cluster RCT; and e, combined two intervention
arms. df, degrees of freedom; M–H, Mantel–Haenszel.
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Study or subgroup Events Total
Experimental
Events Total
Control Odds ratio
M–H, random, 95% CI
Odds ratio
M–H, random, 95% CIWeight (%)
IPD available
Dodd72 2014
Khoury76 2005
Poston68 2015
Walsh78 2012
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 2.73, df = 3 (p = 0.43); I2 = 0%
Test for overall effect: z = 1.03 (p = 0.30)
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 2.73, df = 3 (p = 0.43); I2 = 0%
Test for overall effect: z = 1.03 (p = 0.30)
Test for subgroup differences: Not applicable
5
0
3
1
9
1108
141
783
394
2426
0
1
2
0
3
1104
149
772
406
2431
19.1
15.5
49.8
15.6
100.0
11.01 (0.61 to 199.35)
0.35 (0.01 to 8.66)
1.48 (0.25 to 8.89)
3.10 (0.13 to 76.30)
1.95 (0.55 to 6.90)
9
2426
3
2431 100.0 1.95 (0.55 to 6.90)
1.00
Favours (control)Favours (experimental)
10.00 100.000.100.01
FIGURE 27 Outcome: IUD. df, degrees of freedom; M–H, Mantel–Haenszel.
Study or subgroup Events Total
Experimental
Events Total
Control Odds ratio
M–H, random, 95% CI
Odds ratio
M–H, random, 95% CIWeight (%)
Only aggregate data
de Oliveria Melo48 2012
Deveer32 2013
Hopkins146 2010
Vesco149 2014
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.66, df = 3 (p = 0.88); I2 = 0%
Test for overall effect: z = 0.37 (p = 0.71)
IPD available
Jeffries92 2009
Luoto62 2011
Nascimento84 2011
Poston68 2015
Rauh63 2013
Renault69 2014a
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.02; χ2 = 3.27, df = 3 (p = 0.35); I2 = 8%
Test for overall effect: z = 1.15 (p = 0.25)
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 4.03, df = 7 (p = 0.78); I2 = 0%
Test for overall effect: z = 1.42 (p = 0.16)
Test for subgroup differences: χ2 = 0.07, df = 1 (p = 0.79); I2 = 0%
8
5
4
3
20
114
50
49
58
271
4
3
3
4
14
57
50
49
60
216
7.0
4.9
4.5
4.6
21.0
1.00 (0.29 to 3.47)
1.74 (0.39 to 7.71)
1.36 (0.29 to 6.44)
0.76 (0.16 to 3.57)
1.15 (0.56 to 2.36)
9
10
2
53
6
11
75
148
0
40
783
0
284
1255
12
5
1
38
3
2
53
138
0
42
772
0
141
1093
13.5
1.8
59.0
4.7
79.0
0.68 (0.28 to 1.67)
Not estimable
2.16 (0.19 to 24.77)
1.40 (0.91 to 2.15)
Not estimable
2.80 (0.61 to 12.81)
1.29 (0.84 to 1.99)
95
1526
67
1309 100.0 1.27 (0.91 to 1.77)
1.00
Favours (control)Favours (experimental)
10.00 100.000.100.01
FIGURE 28 Outcome: SGA infant. a, Combined two intervention arms. df, degrees of freedom;
M–H, Mantel–Haenszel.
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Study or subgroup Events Total
Experimental
Events Total
Control Odds ratio
M–H, random, 95% CI
Odds ratio
M–H, random, 95% CIWeight (%)
Only aggregate data
de Oliveria Melo48 2012
Deveer32 2013
Hui52 2014
Vesco149 2014
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.39; χ2 = 5.94, df = 3 (p = 0.11); I2 = 49%
Test for overall effect: z = 1.89 (p = 0.06)
IPD available
Dodd72 2014
Hui91 2012
Jeffries92 2009
Luoto62 2011
Nascimento84 2011
Oostdam75 2012
Poston68 2015a
Prevedel86 2003
Rauh63 2013
Renault69 2014b
Vinter70 2011
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 6.75, df = 8 (p = 0.56); I2 = 0%
Test for overall effect: z = 0.36 (p = 0.72)
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.06; χ2 = 19.00, df = 12 (p = 0.09); I2 = 37%
Test for overall effect: z = 0.92 (p = 0.36)
Test for subgroup differences: χ2 = 3.24, df = 1 (p = 0.07); I2 = 69.2%
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114
50
57
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279
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4
15
37
57
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56
60
223
4.8
2.6
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4.9
15.8
0.47 (0.16 to 1.40)
0.15 (0.03 to 0.71)
1.53 (0.41 to 5.74)
0.28 (0.10 to 0.84)
0.43 (0.18 to 1.03)
203
12
8
26
8
6
96
2
10
17
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375
1108
112
148
0
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62
783
29
0
284
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2746
224
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34
8
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9
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371
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138
0
42
59
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31
0
141
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2579
24.1
7.8
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4.9
1.4
20.4
1.6
7.4
10.4
84.2
0.88 (0.71 to 1.09)
0.78 (0.35 to 1.74)
0.66 (0.26 to 1.69)
Not estimable
1.06 (0.36 to 3.17)
6.21 (0.72 to 53.27)
1.16 (0.85 to 1.59)
1.07 (0.14 to 8.17)
Not estimable
0.93 (0.41 to 2.15)
1.32 (0.69 to 2.54)
0.97 (0.83 to 1.14)
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FIGURE 29 Outcome: LGA infant. a, > 90th centile population birthweight; and b, combined two intervention arms.
df, degrees of freedom; M–H, Mantel–Haenszel.
Study or subgroup Events Total
Experimental
Events Total
Control Odds ratio
M–H, random, 95% CI
Odds ratio
M–H, random, 95% CIWeight (%)
Only aggregate data
Deveer32 2013
Vesco149 2014
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.06, df = 1 (p = 0.81); I2 = 0%
Test for overall effect: z = 2.27 (p = 0.02)
IPD available
Dodd72 2014
Poston68 2015
Stafne88 2012
Vinter70 2011
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 1.00, df = 3 (p = 0.80); I2 = 0%
Test for overall effect: z = 0.37 (p = 0.71)
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.02; χ2 = 6.37, df = 5 (p = 0.27); I2 = 22%
Test for overall effect: z = 0.41 (p = 0.68)
Test for subgroup differences: χ2 = 5.31, df = 1 (p = 0.02); I2 = 81.2%
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FIGURE 30 Outcome: admissions to the NICU. df, degrees of freedom; M–H, Mantel–Haenszel.
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Appendix 10 Search strategies for systematic
reviews undertaken to inform economic modelling
TABLE 56 Example of a search strategy for the systematic review of studies considering the costs associated with
hypertensive disorders in pregnancy: MEDLINE
# Term
1 Pre-Eclampsia/ or preeclamp*.mp.
2 pre-eclamp*.mp.
3 (pre and eclamp*).mp.
4 (pregnan* and hypertens*).mp.
5 Eclampsia/ or eclampsia.mp.
6 (EPH-gestosis or gestosis).mp.
7 (hypertension and pregnancy).mp.
8 Hypertension, Pregnancy-Induced/
9 Hypertension/
10 Pregnancy/
11 9 and 10
12 cost benefit analysis.mp. or exp Cost-Benefit Analysis/
13 (cost$ adj2 (effective$ or utili$ or benefit$ or consequence$ or minimi$)).ti,ab,kw.
14 (decision adj (analy$ or model$ or tree$)).ti,ab,kw.
15 (cost$ or economic$ or pharmacoeconomic$).ti.
16 quality-adjusted life year$.ti,ab,kw. or exp Quality-adjusted Life Years/
17 exp “costs and cost analysis”/ or exp Health Care Costs/
18 exp Economics, Pharmaceutical/ or exp Economics, Medical/ or Economics/ or exp Economics, hospital/
19 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 11
20 12 or 13 or 14 or 15 or 16 or 17 or 18
21 19 and 20
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TABLE 57 Example of a search strategy for the systematic review of studies considering the costs associated with
GDM in pregnancy: MEDLINE
# Term
1 Diabetes, Gestational/
2 (diabet$ adj3 (“pregnancy induced” or gestat$ or gravid$)).ti,ab.
3 GDM.ti,ab.
4 exp DIABETES MELLITUS/
5 diabet$.ti.
6 PREDIABETIC STATE/
7 prediabet$.ti,ab.
8 impaired glucose tolerance.ti,ab.
9 IGT.ti,ab.
10 Impaired fasting glucose.ti,ab.
11 IFG.ti,ab.
12 Impaired glucose regulation.ti,ab.
13 IGR.ti,ab.
14 GLUCOSE INTOLERANCE/
15 PREGNANCY/
16 (pregnan$ or gestation$).ti,ab.
17 PREGNANT WOMEN/
18 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
19 15 or 16 or 17
20 18 and 19
21 1 or 2 or 3 or 20
22 cost benefit analysis.mp. or exp Cost-Benefit Analysis/
23 (cost$ adj2 (effective$ or utili$ or benefit$ or consequence$ or minimi$)).ti,ab,kw.
24 (decision adj (analy$ or model$ or tree$)).ti,ab,kw.
25 (cost$ or economic$ or pharmacoeconomic$).ti.
26 quality-adjusted life year$.ti,ab,kw. or exp Quality-adjusted Life Years/
27 exp “costs and cost analysis”/ or exp Health Care Costs/
28 exp Economics, Pharmaceutical/ or exp Economics, Medical/ or Economics/ or exp Economics, hospital/
29 22 or 23 or 24 or 25 or 26 or 27 or 28
30 21 and 29
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TABLE 58 Example of a search strategy for the systematic review of studies considering the costs and benefits of
interventions to manage weight gain in pregnancy: MEDLINE
# Term
1 Pregnant Women/
2 Gravidity/
3 gravid*.tw.
4 pregnan*.tw.
5 childbearing.tw.
6 matern*.tw.
7 1 or 2 or 3 or 4 or 5 or 6 or 7
8 Weight Gain/ph [Physiology]
9 obes*.tw.
10 overweight*.tw.
11 bmi.tw.
12 Body Mass Index/
13 weight los*.tw.
14 Weight Loss/ph [Physiology]
15 weight change*.tw.
16 weight control.mp.
17 weight management.mp.
18 weight reduction.mp.
19 diet*.tw.
20 exp Diet/
21 nutritional therapy.mp.
22 food restriction.mp. or Caloric Restriction/
23 fast$.mp.
24 Energy Intake/ph [Physiology]
25 Exercise/ or Exercise Therapy/ or exercise$.mp.
26 exercis*.tw.
27 aerobics.mp.
28 physical activit*.tw.
29 calisthenics.mp. or Gymnastics/
30 Diabetes, Gestational/
31 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or
27 or 28 or 29 or 30
32 economic evaluation$.tw.
33 Cost-Benefit Analysis/ec, mt, og, sn, ut [Economics, Methods, Organization & Administration, Statistics &
Numerical Data, Utilization]
34 cost effectiv*.tw.
35 cost utility.tw.
continued
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TABLE 58 Example of a search strategy for the systematic review of studies considering the costs and benefits of
interventions to manage weight gain in pregnancy: MEDLINE (continued )
# Term
36 cost consequence*.tw.
37 health care cost*.tw.
38 cost*.tw.
39 Economics, Medical/ec, sn [Economics, Statistics & Numerical Data]
40 economic$.mp.
41 decision model*.tw.
42 markov model*.tw.
43 Decision Trees/
44 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44
45 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44
46 8 and 32 and 45
47 limit 46 to humans
48 limit 47 to English language
49 limit 48 to last 15 years
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Appendix 11 Probabilistic sensitivity analysis
additional results
F igures 31–54 show additional results for the PSAs that were conducted. Details of the methods anddiscussion of results are available in Chapter 8.
Additional results of probabilistic sensitivity analysis: primary
analysis for a cohort of 10,000 pregnant women
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FIGURE 32 Incremental CEAC of the intervention for all pregnant women: cases of PE averted.
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FIGURE 31 Incremental cost-effectiveness scatterplot of the intervention compared with care as usual for all
women: cases of PE averted. The mean of the distribution is shown by the blue diamond.
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FIGURE 33 Incremental cost-effectiveness scatterplot of the intervention compared with care as usual for all
pregnant women: cases of GDM averted. The mean of the distribution is shown by the blue diamond.
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FIGURE 34 Incremental CEAC of the intervention for all pregnant women: cases of GDM averted.
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FIGURE 35 Incremental cost-effectiveness scatterplot of the intervention compared with care as usual for all
pregnant women: cases of PIH averted. The mean of the distribution is shown by the blue diamond.
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Additional results of probabilistic sensitivity analysis: secondary
analysis for a cohort of 10,000 obese pregnant women
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FIGURE 37 Incremental cost-effectiveness scatterplot of the intervention compared with care as usual for obese
pregnant women: cases of PE averted. The mean of the distribution is shown by the blue diamond.
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FIGURE 36 Incremental CEAC of the intervention for all pregnant women: cases of PIH averted.
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FIGURE 38 Incremental CEAC of the intervention for obese pregnant women: cases of PE averted.
–1500
–1000
–500
0
500
In
cr
em
en
ta
l c
o
st
 (
£) 1000
1500
2000
–0.08 –0.06 –0.04 –0.02 0.00
Incremental effectiveness
0.02 0.04 0.06 0.08
FIGURE 39 Incremental cost-effectiveness scatterplot of the intervention compared with care as usual for obese
women: cases of GDM averted. The mean of the distribution is shown by the blue diamond.
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FIGURE 40 Incremental CEAC of the intervention for obese pregnant women: cases of GDM averted.
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FIGURE 42 Incremental CEAC of the intervention for obese pregnant women: cases of PIH averted.
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FIGURE 41 Incremental cost-effectiveness scatterplot of the intervention compared with care as usual for obese
women: cases of PIH averted. The mean of the distribution is shown by the blue diamond.
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Additional results of probabilistic sensitivity analysis: secondary
analysis for a cohort of 10,000 overweight pregnant women
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FIGURE 44 Incremental CEAC of the intervention for overweight pregnant women: cases of PE averted.
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FIGURE 43 Incremental cost-effectiveness scatterplot of the intervention compared with care as usual for
overweight women: cases of PE averted. The mean of the distribution is shown by the blue diamond.
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FIGURE 47 Incremental cost-effectiveness scatterplot of intervention compared with care as usual for overweight
pregnant women: case of PIH averted. The mean of the distribution is shown by the blue diamond.
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FIGURE 45 Incremental cost-effectiveness scatterplot of intervention compared with care as usual for overweight
women: case of GDM averted. The mean of the distribution is shown by the blue diamond.
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FIGURE 46 Incremental CEAC of intervention for overweight pregnant women: case of GDM averted.
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Additional results of probabilistic sensitivity analysis: secondary
analysis for a cohort of 10,000 normal weight pregnant women
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FIGURE 49 Incremental cost-effectiveness scatterplot of intervention compared with care as usual for normal
weight pregnant women: case of PE averted. The mean of the distribution is shown by the blue diamond.
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FIGURE 48 Incremental CEAC of intervention for overweight pregnant women: case of PIH averted.
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FIGURE 51 Incremental cost-effectiveness scatterplot of intervention compared with care as usual for normal
weight pregnant women: case of GDM averted. The mean of the distribution is shown by the blue diamond.
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FIGURE 50 Incremental CEAC of intervention for normal weight pregnant women: case of PE averted.
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FIGURE 52 Incremental CEAC of intervention for normal weight pregnant women: case of GDM averted.
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FIGURE 53 Incremental cost-effectiveness scatterplot of intervention compared with care as usual for normal
weight pregnant women: case of PIH averted. The mean of the distribution is shown by the blue diamond.
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FIGURE 54 Incremental CEAC of intervention for normal weight pregnant women: case of PIH averted.
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
158

Part of the NIHR Journals Library 
www.journalslibrary.nihr.ac.uk
Published by the NIHR Journals Library
This report presents independent research funded by the 
National Institute for Health Research (NIHR). The views 
expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health
EME
HS&DR
HTA
PGfAR
PHR
